Advertisement

Gout pp 91-185 | Cite as

Clinical Aspects of Gout and Associated Disease States

  • David S. Newcombe
Chapter

Abstract

The presentation of gout and its various stages from acute to chronic is reviewed in detail. Associated dietary and genetic factors and their presentation are reviewed. This chapter forms the basis for the diagnosis and management of gout that are discussed in subsequent chapters.

References

  1. 1.
    Hausch R, Wilkerson M, Singh E, Reyes C, Harrington T. Tophaceous gout of the thoracic spine presenting as back pain and fever. J Clin Rheumatol. 1999;6:335–41.CrossRefGoogle Scholar
  2. 2.
    Marsaudon E, Bouchard C, Languard D. Compression radiculaire par un tophus goutteux vertebral: a propos d’un cas et revue de la literature. Rev Med Interne. 1999;20:253–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Kao MC, Huang SC, Chiu CT, Yao YT. Thoracic cord compression due to gout: a case report and literature review. J Formos Med Assoc. 2000;98:572–5.Google Scholar
  4. 4.
    Mekelburg K, Rahimi AR. Gouty arthritis of the spine: clinical presentation and effective treatments. Geriatrics. 2000;55:71–4.PubMedGoogle Scholar
  5. 5.
    Paquette S, Lach B, Guiot B. Lumbar radiculopathy secondary to gouty tophi in the filum terminale in a patient with systemic gout: case report. Neurosurgery. 2000;46:986–8.PubMedGoogle Scholar
  6. 6.
    Gines R, Bates DJ. Tophaceous lumbar gout mimicking an epidural abscess. Am J Emerg Med. 1998;16:216.PubMedCrossRefGoogle Scholar
  7. 7.
    Vargo J, Giampaolo C, Goldenberg DC. Tophaceous gout of the spine in a patient with no peripheral tophi: case report. Arthritis Rheum. 1985;28:1312–5.CrossRefGoogle Scholar
  8. 8.
    Pascual E. The diagnosis of gout and CPPD crystal arthropathy. Br J Rheumatol. 1996;35:306–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18:1232–4.PubMedGoogle Scholar
  10. 10.
    Pascual E, Batele-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131:756–9.PubMedGoogle Scholar
  11. 11.
    Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1991;91:56–7.Google Scholar
  12. 12.
    Ronault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joints in gout patients and hyperuricemic controls. Arthritis Rheum. 1982;25:209–12.CrossRefGoogle Scholar
  13. 13.
    Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of untreated gout. Arthritis Rheum. 1991;34:141–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Chopra KF, Schneiderman P, Grossman ME. Finger pad tophi. Cutis. 1999;64:233–6.PubMedGoogle Scholar
  15. 15.
    Marcen R, Gallego N, Orofino L, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron. 1995;70:307–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Lin HY, Rocher LL, McQuilan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321:287–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Baethge BA, Work J, Landreneau MD, McDonald JC. Tophaceous gout in patients with renal transplants treated with cyclosporine A. J Rheumatol. 1993;20:2171.Google Scholar
  18. 18.
    Chaoui A, Garcia J, Kurt AM. Gouty tophus simulating soft tissue tumor in a heart transplant recipient. Skeletal Radiol. 1997;26:626–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30:951–3.PubMedGoogle Scholar
  20. 20.
    Jagose JT, Bailey RR. Muscle weakness due to colchicine in a renal transplant recipient. N Z Med J. 1997;110:343.PubMedGoogle Scholar
  21. 21.
    Tapal MF. Colchicine myopathy. Scand J Rheumatol. 1996;25:105.PubMedCrossRefGoogle Scholar
  22. 22.
    Gruberg L, Har-Zahav Y, Agranat O, Freimark D. Acute myopathy induced by colchicine treated heart transplant recipient: possible role of the multidrug resistance transporter. Transplant Proc. 1999;31:2157–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporine-A treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9:549–51.Google Scholar
  24. 24.
    Loeb JN. The influence of temperature of the solubility of monosodium urate. Arthritis Rheum. 1972;15:189.PubMedCrossRefGoogle Scholar
  25. 25.
    Kelley WN. Approach to the patient with hyperuricemia. In: Kelley WN, Harris Jr ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders; 1981. p. 494.Google Scholar
  26. 26.
    Adler R, Robinson R, Pazdral P, Grushkin C. Hyperuricemia in diarrheal dehydration. Am J Dis Child. 1969;136:564.Google Scholar
  27. 27.
    Faller J, Fox IH. Ethanol-induced hyperuricemia. Evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med. 1980;307:1598.CrossRefGoogle Scholar
  28. 28.
    Weinberger A, Schumacher HR, Schimmer BM, et al. Arthritis in acute leukemia. Clinical and histopathological observations. Arch Intern Med. 1981;141:1183.PubMedCrossRefGoogle Scholar
  29. 29.
    Dosman JA, Crawhall JC, Klassen GA. Uric acid kinetic studies in the immediate post-myocardial infarction period. Metabolism. 1975;24:473.PubMedCrossRefGoogle Scholar
  30. 30.
    Levine SA, Gordon B, Derick CL. Some changes in the chemical constituents of the blood following a marathon race. JAMA. 1924;82:1778.CrossRefGoogle Scholar
  31. 31.
    Schrier RW, Haus J, Keller HI, et al. Renal, metabolic and circulatory responses to heat and exercise. Ann Intern Med. 1970;73:213.PubMedGoogle Scholar
  32. 32.
    Knochel JP, Dotin LN, Hamburger RJ. Heat stress, exercise, and muscle injury: effects on urate metabolism and renal function. Ann Intern Med. 1974;81:321.PubMedGoogle Scholar
  33. 33.
    Quick AJ. The effect of exercise on excretion of uric acid. J Biol Chem. 1935;110:107.Google Scholar
  34. 34.
    Castenfors J. Renal function during exercise. Acta Physiol Scand Suppl. 1967;70:7.Google Scholar
  35. 35.
    Knochel JP. Biochemical, electrolyte, and acid–base disturbances in acute renal failure. In: Brenner BM, Lazarus JM, editors. Acute renal failure. New York: Churchill Livingstone; 1988. p. 682–3.Google Scholar
  36. 36.
    Lacocq FR, McPhaul JJ. Effects of starvation, high fat diets and ketone infusions on uric acid balance. Metabolism. 1965;14:186.CrossRefGoogle Scholar
  37. 37.
    Ravioko KO. Neonatal hyperuricemia. J Pediatr. 1976;88:625.CrossRefGoogle Scholar
  38. 38.
    Valat JP, Lamisse F, LeChevallier PL, et al. Les variations de l’uricemie au cours de’ compensations respiratories aigues des bronchopathies chroniques. Rev Rhum Mal Osteoartic. 1974;41:179.PubMedGoogle Scholar
  39. 39.
    Bergeaux G, Klein RC. Hyperuricemia following smoke inhalation. Am Rev Respir Dis. 1974;109:145.PubMedGoogle Scholar
  40. 40.
    Oliva PB. Lactic acidosis. Am J Med. 1970;48:209.PubMedCrossRefGoogle Scholar
  41. 41.
    Saker BM, Tofler OB, Burvill MJ, Reilly KA. Alcohol consumption and gout. Med J Aust. 1967;1:1213.PubMedGoogle Scholar
  42. 42.
    Pell S, D’Alonzo CA. The prevalence of chronic disease among problem drinkers. Arch Environ Health. 1968;16:679.PubMedGoogle Scholar
  43. 43.
    Beck LH. Clinical disorders of uric acid metabolism. Med Clin North Am. 1981;65:401.PubMedGoogle Scholar
  44. 44.
    Puig JG, Fox IH. Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate. J Clin Invest. 1984;74:936.PubMedCrossRefGoogle Scholar
  45. 45.
    Shergy WJ, Gilkeson GS, German DC. Acute gouty arthritis and intravenous nitroglycerin. Arch Intern Med. 1988;148:2505.PubMedCrossRefGoogle Scholar
  46. 46.
    Daly RJ, Camann WR, Dawley D, O’Rourke ME. “Cocktail”-coronary care. N Engl J Med. 1984;310:1123.PubMedGoogle Scholar
  47. 47.
  48. 48.
    Dylewski JS, Gerson M. Hyperuricemia in patients with infectious mononucleosis. Can Med Assoc J. 1985;132:1169.PubMedGoogle Scholar
  49. 49.
    Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine. 1979;58:270.PubMedCrossRefGoogle Scholar
  50. 50.
    Alexander RD, Barkes SL, Abuelo G. Contrast media-induced oliguric renal failure. Arch Intern Med. 1978;138:381.PubMedCrossRefGoogle Scholar
  51. 51.
    Krumlovsky FA, Simon N, Santhanam S, et al. Acute renal failure associated with administration of radiographic contrast material. JAMA. 1978;239:125.PubMedCrossRefGoogle Scholar
  52. 52.
    Fang LS, Sirota RA, Ebert TH, Lichenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med. 1980;140:531.PubMedCrossRefGoogle Scholar
  53. 53.
    Shafi T, Chou S-Y, Porush JS, Shapiro WB. Infusion intravenous pyelography and renal function. Effects in patients with chronic renal insufficiency. Arch Intern Med. 1978;138:1218.PubMedCrossRefGoogle Scholar
  54. 54.
    Older RA, Korobkin M, Cleeve DM, et al. Contrast-induced acute renal failure. Persistent nephrogram as a clue to early detection. AJR Am J Roentgenol. 1980;134:339.PubMedGoogle Scholar
  55. 55.
    Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36:561.PubMedCrossRefGoogle Scholar
  56. 56.
    Hoefnagel D, Andrew ED, Mireault NG, Berndt WO. Hereditary choreoathetosis, self-mutilation, and hyperuricemia in young males. N Engl J Med. 1965;273:130.PubMedCrossRefGoogle Scholar
  57. 57.
    Michener WM. Hyperuricemia and mental retardation with athetosis and self-mutilation. Am J Dis Child. 1967;113:195.PubMedGoogle Scholar
  58. 58.
    Dreifuss FE, Newcombe DS, Shapiro SL, Sheppard GL. X-linked primary hyperuricemia (hypoxanthine-guanine phosphoribosyltransferase deficiency encephalopathy). J Ment Defic Res. 1968;12:100.PubMedGoogle Scholar
  59. 59.
    Munsat TL, Klinenberg J, Carrel RE, Menkes J. Defects in purine metabolism and neurologic disease. Bull Los Angeles Neurol Soc. 1968;33:101.PubMedGoogle Scholar
  60. 60.
    Berman PH, Balis ME, Dancis J. Congenital hyperuricemia, an inborn error of purine metabolism associated with psychomotor retardation, athetosis, and self-mutilation. Arch Neurol. 1969;20:44.PubMedCrossRefGoogle Scholar
  61. 61.
    Rosenberg D, Monnet P, Mamelle JL, Colonbel M, et al. Encephalopathie avec troubles due metabolisme des purines. Presse Med. 1968;76:2333.Google Scholar
  62. 62.
    Riley JD. Gout and cerebral palsy in a three-year-old boy. Arch Dis Child. 1960;35:293.PubMedCrossRefGoogle Scholar
  63. 63.
    Partington MW, Hennen BKE. The Lesch-Nyhan syndrome: self-destructive biting, mental retardation, neurological disorder and hyperuricemia. Dev Med Child Neurol. 1967;9:563.PubMedCrossRefGoogle Scholar
  64. 64.
    Scherzer AL, Ilson JB. Normal intelligence in the Lesch-Nyhan syndrome. Pediatrics. 1969;44:116.PubMedGoogle Scholar
  65. 65.
    Buitelaar JK. Self-injurious behavior in retarded children: clinical phenomena and biological mechanisms. Acta Paedopsychiatr. 1993;56:105–11.PubMedGoogle Scholar
  66. 66.
    Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA. 1996;93:5539–43.PubMedCrossRefGoogle Scholar
  67. 67.
    Harris JC, Lee RR, Jinnah HA, et al. Craniocerebral magnetic resonance imaging measurement and findings in Lesch-Nyhan syndrome. Arch Neurol. 1998;55:547–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Visser JE, Bar PR, Jinnah H. Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev. 2000;32:449–75.PubMedCrossRefGoogle Scholar
  69. 69.
    Roach ES, Delgado M, Anderson L, et al. Carbama­zepine trial for Lesch-Nyhan self-mutilation. J Child Neurol. 1996;11:476–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Hernandez-Nieto L, Brito-Barraso ML, Nyhan WL. Megaloblastic anemia in Lesch-Nyhan disease. Sangre. 1984;29:476.PubMedGoogle Scholar
  71. 71.
    Van der Zee SPM, Monnens LAH, Schretlen EDAM. Hereditary disorder of purine metabolism with cerebral affection and megaloblastic anemia. Ned Tijdschr Geneeskd. 1968;112:1475.PubMedGoogle Scholar
  72. 72.
    Kelley WN, Greene ML, Rosenbloom FM, et al. Hypoxanthine-guanine phosphoribosyltransferase in gout. Ann Intern Med. 1969;70:155.PubMedGoogle Scholar
  73. 73.
    Schneider W. The Lesch-Nyhan syndrome as a rare cause of hemolytic anemia. Acta Med Austriaca. 1979;6:202.PubMedGoogle Scholar
  74. 74.
    Van der Zee SPM, Schretlen EDAM, Monnens LAH. Megaloblastic anemia in the Lesch-Nyhan syndrome. Lancet. 1968;1:1427.PubMedGoogle Scholar
  75. 75.
    Zoref-Shani E, Feinstein S, Frishberg Y, et al. Kelley-Seegmiller syndrome due to a unique variant of hypoxanthine-guanine phosphoribosyltransferase: reduced affinity for 5-phosphoribosyl-1-pyrophosphate manifested only at low, physiological substrate concentrations. Biochim Biophys Acta. 2000;1500:197–203.PubMedCrossRefGoogle Scholar
  76. 76.
    Wingen RM, Loffler W, Waldherr R, Scharer K. Acute renal failure in an infant with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:751–5.PubMedGoogle Scholar
  77. 77.
    Sperling O, Boer P, Persky-Brosh S, et al. Altered kinetic property of erythrocyte phosphoribosyl-pyrophosphate synthetase in excessive purine production. Rev Eur Etud Clin Biol. 1972;17:703.PubMedGoogle Scholar
  78. 78.
    Becker MA, Losman MJ, Kim M. Mechanisms of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetases. J Biol Chem. 1987;262:5596.PubMedGoogle Scholar
  79. 79.
    Zoref E, de Vries A, Sperling O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J Clin Invest. 1975;56:1093.PubMedCrossRefGoogle Scholar
  80. 80.
    Ahmed M, Taylor W, Smith PR, Becker MA. Accelerated transcription of PRS1 in x-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem. 1999;274:7482.PubMedCrossRefGoogle Scholar
  81. 81.
    Becker MA, Puig JG, Mateos FA, et al. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988;85:393.Google Scholar
  82. 82.
    Becker MA, Raivio KO, Bakay B, et al. Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J Clin Invest. 1980;65:109.PubMedCrossRefGoogle Scholar
  83. 83.
    Simmonds HA, Webster DR, Lingham S, Wilson J. An inborn error of purine metabolism, deafness and neurodevelopmental abnormality. Neuropediatrics. 1985;16:106.PubMedCrossRefGoogle Scholar
  84. 84.
    Becker MA, Smith PR, Taylor W, et al. The genetic and functional basis of purine nucleotide feedback resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest. 1995;96:2133.PubMedCrossRefGoogle Scholar
  85. 85.
    Zoref E, de Vries A, Sperling O. Metabolic cooperation between human fibroblasts with normal and with mutant superactive phosphoribosylpyrophosphate synthetase. Nature. 1976;260:787.PubMedCrossRefGoogle Scholar
  86. 86.
    Yen RCK, Adams WB, Lazar C, Becker MA. Evidence for x-linkage of human phosphoribosyl-pyrophosphate synthetase. Proc Natl Acad Sci USA. 1978;75:482.PubMedCrossRefGoogle Scholar
  87. 87.
    Simmonds HA, Webster DR, Wilson J, Lingham S. An X-linked syndrome characterized by hyperuricaemia, deafness, and neurodevelopmental abnormalities. Lancet. 1982;2:68.PubMedCrossRefGoogle Scholar
  88. 88.
    Henderson JF, Caldwell IC, Patterson ARP. Decreased feedback inhibition in a 6-methylmercaptopurine ribonucleoside-resistant tumor. Cancer Res. 1967;27:1773.PubMedGoogle Scholar
  89. 89.
    Nagy M. Regulation of the biosynthesis of purine nucleotides in Schizosaccharomyces pombe. I. Properties of the phosphoribosylpyrophosphate: glutamine amidotransferase of the wild strain and of a mutant desensitized towards feedback modifiers. Biochim Biophys Acta (Amst). 1971;198:471.CrossRefGoogle Scholar
  90. 90.
    Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism. 1981;30:616.PubMedCrossRefGoogle Scholar
  91. 91.
    Fox IH, Palella TD, Kelley WN. Hyperuricemia: a marker for cell energy crisis. N Engl J Med. 1987;317:111.PubMedCrossRefGoogle Scholar
  92. 92.
    Fox IH. Adenosine triphosphate degradation in specific disease. J Lab Clin Med. 1985;106:101.PubMedGoogle Scholar
  93. 93.
    Alexander D, Assaf M, Khudr A, et al. Fructose-1,6-diphosphatase deficiency: diagnosis using leukocytes and detection of heterozygotes with radiochemical and spectrophotometric methods. J Inherit Metab Dis. 1985;8:147.CrossRefGoogle Scholar
  94. 94.
    Gitzelmann R, Steinmann B, Van den Berghe G. Disorders of fructose metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc; 1995. p. 905–34.Google Scholar
  95. 95.
    Melancon SB, Khachadurian AK, Nadler HL, Brown BI. Metabolic and biochemical studies in fructose-1,6-diphosphatase deficiency. J Pediatr. 1973;82:650.PubMedCrossRefGoogle Scholar
  96. 96.
    Baerlocher K, Gitzelmann R, Nassli R, Dumermuth G. Infantile lactic acidosis due to hereditary fructose-1,6-diphosphatase deficiency. Helv Paediatr Acta. 1971;26:489.PubMedGoogle Scholar
  97. 97.
    Hopwood NJ, Holzman I, Drash AL. Fructose-1,6-diphosphatase deficiency. Am J Dis Child. 1977;131:418.PubMedGoogle Scholar
  98. 98.
    Corbell L, Eggermont E, Eeckels R, et al. Recurrent attacks of ketotic acidosis associated with fructose-1,6-diphosphatase deficiency. Acta Paediatr Belg. 1976;29:29.Google Scholar
  99. 99.
    Corbell LM, Eggermont E, Bettens W, et al. Fructose intolerance with normal liver aldolase. Helv Paediatr Acta. 1970;25:626.Google Scholar
  100. 100.
    Steinmann B, Gitzelmann R. Fruktose und sorbitol infusions flussigkeiten sind nicht immer hamlos. Int J Vitam Nutr Res Suppl. 1976;15:239.Google Scholar
  101. 101.
    Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med. 1982;72:58.PubMedCrossRefGoogle Scholar
  102. 102.
    Woolliscroft JO, Fox IH. Increased body fluid purines during hypotensive events: evidence for ATP degradation. Am J Med. 1986;81:472.PubMedCrossRefGoogle Scholar
  103. 103.
    Grum CM, Simon RH, Dantzker DR, Fox IH. Biochemical indicators of cellular hypoxia in critically ill patients: evidence for ATP degradation. Chest. 1985;88:763.PubMedCrossRefGoogle Scholar
  104. 104.
    Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713.PubMedCrossRefGoogle Scholar
  105. 105.
    Christensen EF, Jacobsen J, Anker-Moller E, et al. Increased urinary loss of uric acid in adults with acute respiratory failure requiring mechanical ventilation. Chest. 1992;102:556.PubMedCrossRefGoogle Scholar
  106. 106.
    Braghiroli A, Sacco C, Erbetta M, et al. Overnight urinary uric acid: creatinine ration for detection of sleep hypoxemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. Am Rev Respir Dis. 1993;148:173.PubMedGoogle Scholar
  107. 107.
    Mateos AF, Puig JG, Gomez Fernandez P, et al. Degradation of purine nucleotides in patients with chronic obstructive airflow. Med Clin (Barc). 1989;92:328.Google Scholar
  108. 108.
    Karlsson J, Willerson JT, Leshin SJ, et al. Skeletal muscle metabolites in patients with cardiogenic shock or severe congestive heart failure. Scand J Clin Lab Invest. 1975;35:73.PubMedCrossRefGoogle Scholar
  109. 109.
    Buhl L, Vilhelmsen KN, Nielsen JR. Oxypurine release in cardiac disease. Acta Med Scand. 1981;209:83.PubMedCrossRefGoogle Scholar
  110. 110.
    Sangstad OD. Hypoxanthine as a measurement of hypoxia. Pediatr Res. 1975;9:158.CrossRefGoogle Scholar
  111. 111.
    Harkness RA, Simmonds RJ, Coade SB, Lawrence CR. Ratio of the concentration of hypoxanthine to creatinine in urine from newborn infants: a possible indicator for the metabolic damage due to hypoxia. Br J Obstet Gynaecol. 1983;90:447.PubMedCrossRefGoogle Scholar
  112. 112.
    Harkness RA, Whitelow AGL, Simmonds RJ. Intrapartum hypoxia: the association between neurological assessment of damage and abnormal excretion of ATP metabolites. J Clin Pathol. 1982;35:999.PubMedCrossRefGoogle Scholar
  113. 113.
    Manzke H, Dorner K, Grunitz J. Urinary hypoxanthine, xanthine and uric acid excretion in newborn infants with perinatal complications. Acta Paediatr Scand. 1977;66:713.PubMedCrossRefGoogle Scholar
  114. 114.
    Jensen MH, Brinklov MM, Lillquist K. Urinary loss of oxypurines in hypoxic premature neonates. Biol Neonate. 1980;38:40.PubMedCrossRefGoogle Scholar
  115. 115.
    Raivio KO. Neonatal hyperuricemia. J Pediatr. 1976;88:625.PubMedCrossRefGoogle Scholar
  116. 116.
    Swanstrom S, Bratteby L. Hypoxanthine as a test of perinatal hypoxia as compared to lactate, base deficit, and pH. Pediatr Res. 1982;16:156.PubMedCrossRefGoogle Scholar
  117. 117.
    Thiringer K. Cord plasma hypoxanthine as a measure of foetal asphyxia. Acta Paediatr Scand. 1983;72:231.PubMedCrossRefGoogle Scholar
  118. 118.
    Fruhmann G, Fritz H, Bergstermann H. Homozygous inherited alpha1-antitrypsin deficiency with emphysema of the lung, cor pulmonale, and gout. Klin Wochenschr. 1974;52:80.PubMedCrossRefGoogle Scholar
  119. 119.
    Kohkhar N. Hyperuricemia and gout in secondary polycythemia due to chronic obstructive pulmonary disease. J Rheumatol. 1980;7:114.PubMedGoogle Scholar
  120. 120.
    Ball GV, Sorensen LB. Pathogenesis of hyperuricemia and gout in sickle cell anemia. Arthritis Rheum. 1970;13:846.PubMedCrossRefGoogle Scholar
  121. 121.
    March HW, Schylen SM, Schwartz SE. Mediterranean hemopathic syndromes (Cooley’s anemia) in adults: study of a family with unusual complications. Am J Med. 1952;13:46.PubMedCrossRefGoogle Scholar
  122. 122.
    Paik CH, Alavi I, Dunea G, Weiner L. Thalassemia and gouty arthritis. JAMA. 1970;213:296.PubMedCrossRefGoogle Scholar
  123. 123.
    Hickling RA. Gout, leukemia, and polycythaemia. Lancet. 1953;1:57.PubMedCrossRefGoogle Scholar
  124. 124.
    Talbott JH. Gout. New York: Grune & Stratton; 1957.Google Scholar
  125. 125.
    Yu TF. Secondary gout associated with myeloproliferative disease. Arthritis Rheum. 1965;8:765.PubMedCrossRefGoogle Scholar
  126. 126.
    Bronsky D, Bernstein A. Acute gout secondary to multiple myeloma: a case report. Ann Intern Med. 1954;41:820.PubMedGoogle Scholar
  127. 127.
    Somerville J. Gout in cyanotic congenital heart disease. Br Heart Med. 1961;23:31.CrossRefGoogle Scholar
  128. 128.
    Zimmer JG, Demus DJ. Associations between gout, psoriasis and sarcoidosis: with consideration of their pathologic significance. Ann Intern Med. 1966;64:786.Google Scholar
  129. 129.
    Van den Berghe G, Hers HG. Abnormal AMP deaminase in primary gout. Lancet. 1980;2:1090.PubMedGoogle Scholar
  130. 130.
    Hers HG, Van den Berghe G. Enzyme defect in primary gout. Lancet. 1979;1:585.PubMedCrossRefGoogle Scholar
  131. 131.
    DiMauro S, Miranda AF, Hays AP, et al. Myoadenylate deaminase deficiency – muscle biopsy and muscle culture in a patient with gout. J Neurol Sci. 1980;47:191–202.PubMedCrossRefGoogle Scholar
  132. 132.
    Sabina RL, Swain JL, Olanow CW, et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 1984;73:720. 30.PubMedCrossRefGoogle Scholar
  133. 133.
    Sabina RL, Holmes EW. Myoadenylate deaminase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc; 1995. p. 1769–80.Google Scholar
  134. 134.
    Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med. 1994;120:218.PubMedGoogle Scholar
  135. 135.
    Abarbanel JM, Potashnik R, Frisher S, et al. Myophosphorylase deficiency: the course of an unusual congenital myopathy. Neurology. 1987;37:316.PubMedCrossRefGoogle Scholar
  136. 136.
    Zanella A, Mariani M, Meola G, Fagnani G, Sirchia G. Phosphofructokinase (PFK) deficiency due to a catalytically inactive mutant M-type subunit. Am J Hematol. 1982;12:215–25.CrossRefGoogle Scholar
  137. 137.
    Tarui S, Okuno G, Ikura Y, et al. Phosphofructokinase deficiency in skeletal muscle: a new type of glycogenosis. Biochem Biophys Res Commun. 1963;19:517–23.CrossRefGoogle Scholar
  138. 138.
    Ambrose DR, McCabe ER, Anderson D, Beaudet A, et al. Infections and bleeding complications in patients with glycogenosis Ib. Am J Dis Child. 1985;139:691–7.Google Scholar
  139. 139.
    Soejimak K, Landing BH, Roe TF, Swanson VL. Pathologic studies of the osteoporosis of Von Gierke’s disease (glycogenosis Ia). Pediatr Pathol. 1985;3:307–19.CrossRefGoogle Scholar
  140. 140.
    De Parscau L, Guiband P, Labrime P, Odievre M. Long-term course of hepatic glycogenosis. A retrospective study of 76 cases. Arch Fr Pediatr. 1988;45:641–5.PubMedGoogle Scholar
  141. 141.
    Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB. Renal disease in type I glycogen storage disease. N Engl J Med. 1988;318:7–11.PubMedCrossRefGoogle Scholar
  142. 142.
    Baker L, Dahlem S, Goldfarb S, et al. Hyperfiltration and renal disease in glycogen storage disease, type I. Kidney Int. 1989;5:1345–50.CrossRefGoogle Scholar
  143. 143.
    Restaino I, Kaplan BS, Stanley C, et al. Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr. 1993;122:392.PubMedCrossRefGoogle Scholar
  144. 144.
    Matsuo N, Tsuchiya Y, Cho H, et al. Proximal renal tubular acidosis in a child with type 1 glycogen storage disease. Acta Paediatr Scand. 1986;75:332.PubMedCrossRefGoogle Scholar
  145. 145.
    Chen YT, Scheinman JI, Park HK, et al. Amelioration of proximal renal tubular dysfunction in type 1 glycogen storage disease with dietary therapy. N Engl J Med. 1990;323:590.PubMedCrossRefGoogle Scholar
  146. 146.
    Howell RR, Stevenson RE, Ben-Menachem Y, Phyliky RL, Berry DH. Hepatic adenomata with type I glycogen storage disease. JAMA. 1976;236:1481.PubMedCrossRefGoogle Scholar
  147. 147.
    Limmer J, Fleig WE, Leupold D, et al. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology. 1988;8:531.PubMedCrossRefGoogle Scholar
  148. 148.
    Fink AS, Appelman HD, Thompson NW. Hemorrhage into a hepatic adenoma and type Ia glycogen storage disease: a case report and review of the literature. Surgery. 1985;97:117.PubMedGoogle Scholar
  149. 149.
    Levy E, Thibault LA, Roy CC, et al. Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding. J Lipid Res. 1988;29:215.PubMedGoogle Scholar
  150. 150.
    Beaudet AL, Anderson DC, Michelis VV, Arion WJ, Lange AJ. Neutropenia and impaired neutrophil migration in type Ib glycogen storage disease. J Pediatr. 1980;97:906.PubMedCrossRefGoogle Scholar
  151. 151.
    Bartram CR, Przyrembel H, Wendel U, et al. Glycogenosis type Ib complicated by severe granulocytopenia resembling inherited neutropenia. Eur J Pediatr. 1981;137:81.PubMedCrossRefGoogle Scholar
  152. 152.
    Murase T, Ikeda H, Muro T, Nakao K, Sugita H. Myopathy associated with type III glycogenosis. J Neurol Sci. 1973;20:287.PubMedCrossRefGoogle Scholar
  153. 153.
    Brunberg JA, McCormick WF, Schochet SS. Type III glycogenosis. An adult with diffuse weakness and muscle wasting. Arch Neurol. 1971;25:171.PubMedCrossRefGoogle Scholar
  154. 154.
    Moses SW, Gadoth N, Bashan N, et al. Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand. 1986;75:289.PubMedCrossRefGoogle Scholar
  155. 155.
    Moses SW, Wanderman KL, Myroz A, Frydman M. Cardiac involvement in glycogen storage disease type III. Eur J Pediatr. 1989;148:764.PubMedCrossRefGoogle Scholar
  156. 156.
    Coleman RA, Winter HA, Wolf B, et al. Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med. 1992;116:896.PubMedGoogle Scholar
  157. 157.
    DiMauro S, Hartwig GB, Hays A, et al. Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol. 1979;5:422.PubMedCrossRefGoogle Scholar
  158. 158.
    Cornelio F, Bresolin N, Singer PA, et al. Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol. 1971;25:171.CrossRefGoogle Scholar
  159. 159.
    Labrime PL, Huguet P, Odievre M. Cardiomyopathy in glycogen-storage disease type III: clinical and echocardiographic study of 18 patients. Pediatr Cardiol. 1991;12:161.CrossRefGoogle Scholar
  160. 160.
    Olson LJ, Reeder GS, Noller KL, et al. Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol. 1984; 53:980.PubMedCrossRefGoogle Scholar
  161. 161.
    Miller CG, Alleyne GA, Brooks SEH. Gross cardiac involvement in glycogen storage disease type III. Br Heart J. 1972;34:862.PubMedCrossRefGoogle Scholar
  162. 162.
    van Crevold S. The Blackader lecture, 1961: the clinical course of glycogen disease. Can Med Assoc J. 1963;88:1–15.Google Scholar
  163. 163.
    Mineo I, Kono N, Hara N, et al. Myogenic hyperuricemia. A common pathologic feature of glycogenosis type III, V and VII. N Engl J Med. 1987;317: 75–80.PubMedCrossRefGoogle Scholar
  164. 164.
    Puig JG, de Miguel E, Mateos FA, et al. McArdle’s disease and gout. Muscle Nerve. 1992;15:822–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Hardiman O, Farrell M, McElvaney G, et al. Hyperuricemia in type V glycogenosis. Neurology. 1987;37:728–9.PubMedCrossRefGoogle Scholar
  166. 166.
    Servidei S, DiMauro S. Disorders of glycogen metabolism of muscle. Neurol Clin. 1989;7:159–78.PubMedGoogle Scholar
  167. 167.
    Moses SW. Muscle glycogenosis. J Inherit Metab Dis. 1990;13:452.PubMedCrossRefGoogle Scholar
  168. 168.
    Pourmand R, Sanders DB, Corwin HM. Late-onset McArdle’s disease with unusual electromyographic findings. Arch Neurol. 1983;40:374.PubMedCrossRefGoogle Scholar
  169. 169.
    Hewlett RH, Gardner-Thorpe C. McArdle’s Disease – what limit to the age of onset? S Afr Med J. 1978;53:60.PubMedGoogle Scholar
  170. 170.
    Mineo I, Kono N, Shimizu T, et al. Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII. J Clin Invest. 1985;76:556–60.PubMedCrossRefGoogle Scholar
  171. 171.
    Jinnai K, Kono N, Yamamoto Y, et al. Glycogenosis type V (McArdle’s disease) with hyperuricemia. Eur Neurol. 1993;33:204–7.PubMedCrossRefGoogle Scholar
  172. 172.
    Higgs JB, Blaivas M, Albers JW. McArdle’s disease presenting as treatment resistant polymyositis. J Rheumatol. 1989;16:1588.PubMedGoogle Scholar
  173. 173.
    Vora S, Davidson M, Seaman C, et al. Heterogeneity of the molecular lesions in inherited phosphofructokinase deficiency. J Clin Invest. 1983;72: 1995–2006.PubMedCrossRefGoogle Scholar
  174. 174.
    Hays AP, Hallet M, Delfs J, et al. Muscle phosphofructokinase deficiency: abnormal polysaccharide in a case of late-onset myopathy. Neurology (NY). 1981;31:1077–86.CrossRefGoogle Scholar
  175. 175.
    Agamanolis DP, Askari AD, DiMauro S, et al. Muscle phosphofructokinase deficiency: two cases with unusual polysaccharide accumulation and immunologically active enzyme protein. Muscle Nerve. 1980;3:456–67.PubMedCrossRefGoogle Scholar
  176. 176.
    Zanella A, Mariani M, Meola G, et al. Phosphofructokinase (PFK) deficiency due to a catalytically inactive mutant M-type subunit. Am J Hematol. 1982;12:215–25.CrossRefGoogle Scholar
  177. 177.
    Nakagawa C, Mineo I, Kaido M, et al. A new variant case of muscle phosphofructokinase deficiency, coexisting with gastric ulcer, gouty arthritis, and increased hemolysis. Muscle Nerve. 1995;3:539–44.Google Scholar
  178. 178.
    Danon MJ, Servidei S, DiMauro S, Vora S. Late-onset muscle phosphofructokinase deficiency. Neurology. 1988;38:956.PubMedCrossRefGoogle Scholar
  179. 179.
    Serratrice G, Monges A, Roux H, et al. Forme myopathique du deficit en phosphofructokinase. Rev Neurol. 1969;120:271.PubMedGoogle Scholar
  180. 180.
    Servidei S, Bonilla E, Diedrick RG, et al. Fatal infantile form of muscle phosphofructokinase deficiency. Neurology. 1986;36:1465.PubMedCrossRefGoogle Scholar
  181. 181.
    Danon MJ, Carpenter S, Manaligod JR, Schlisefeld LH. Fatal infantile glycogen storage disease: deficiency of phosphofructokinase and phosphorylase b kinase. Neurology. 1981;31:1303.PubMedCrossRefGoogle Scholar
  182. 182.
    Vora S, Corash L, Engel WK, et al. The molecular mechanism of the inherited phosphofructokinase deficiency associated with hemolysis and myopathy. Blood. 1980;55:629–35.PubMedGoogle Scholar
  183. 183.
    Shimizu T, Kono N, Kiyokawa H, et al. Erythrocyte glycolysis and its marked alterations by muscular exercise in type VII glycogenosis. Blood. 1988;71:1130.PubMedGoogle Scholar
  184. 184.
    Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med. 1991;324:364.PubMedCrossRefGoogle Scholar
  185. 185.
    Tarui S, Kono N, Kuwajima M, Ikura Y. Type VII glycogenosis (muscle and erythrocyte phosphofructokinase deficiency). Monogr Hum Genet. 1978;9:42–7.PubMedGoogle Scholar
  186. 186.
    Tarui S, Kono N, Nasu T, Nishikawa M. Enzymatic basis for the coexistence of myopathy and hemolytic disease in inherited phosphofructokinase deficiency. Biochem Biophys Res Commun. 1969;34:77–83.PubMedCrossRefGoogle Scholar
  187. 187.
    Tem I. Metabolic myopathies. Pediatr Neurol. 1996;3:53–98.CrossRefGoogle Scholar
  188. 188.
    DiMauro S, Miranda AF, Khan S, et al. Human ­muscle phosphoglycerate mutase deficiency and myoadenylate deaminase deficiency. Science. 1981;212:1277–9.PubMedCrossRefGoogle Scholar
  189. 189.
    Bertorini TE, Shively V, Taylor B, et al. ATP degradation products after ischemic exercise: hereditary lack of phosphorylase or carnitine palmitoyltransferase. Neurology. 1985;35:1355–7.PubMedCrossRefGoogle Scholar
  190. 190.
    Abaranel JM, Bashan N, Potashnik R, et al. Adult phosphorylase b kinase deficiency. Neurology. 1986;36:560.CrossRefGoogle Scholar
  191. 191.
    Servidei S, Metlay LA, Booth FA, et al. Clinical and biochemical heterogeneity of phosphorylase kinase deficiency. Neurology. 1987;37 Suppl 1:139.Google Scholar
  192. 192.
    Clemens PR, Yamamoto M, Engel AG. Adult phosphorylase b kinase deficiency. Ann Neurol. 1990;28:529.PubMedCrossRefGoogle Scholar
  193. 193.
    Laforet P, Eymard B, Lombes A, et al. Intolerance a l’effort par deficit en phosphorylase b kinase musculaire. Apport des investigations metaboliques in vivo. Rev Neurol (Paris). 1996;152:458–64.Google Scholar
  194. 194.
    Fukuda T, Sugie H, Sugie Y, et al. Five cases of phosphorylase b kinase deficiency affecting muscle or liver: clinical symptoms and diagnosis. No To Hattatsu. 1994;26:493–7.PubMedGoogle Scholar
  195. 195.
    Wilkinson DA, Tonin P, Shanske S, et al. Clinical and biochemical features of 10 adult patients with muscle phosphorylase kinase deficiency. Neurology. 1994;44:461–6.PubMedCrossRefGoogle Scholar
  196. 196.
    Carrier H, Maire I, Vial C, et al. Myopathic evolution of an exertional muscle pain syndrome with phosphorylase b kinase deficiency. Acta Neuropathol (Berlin). 1990;81:84–8.CrossRefGoogle Scholar
  197. 197.
    Van den Berg IF, Berger R. Phosphorylase b kinase deficiency in man: a review. J Inherit Metab Dis. 1990;13:442–51.PubMedCrossRefGoogle Scholar
  198. 198.
    Madloni M, Berley GT, Cohen PT, Marrian VJ. Phosphorylase b kinase deficiency in a boy with glycogenosis affecting both liver and muscle. Eur J Pediatr. 1989;149:52–3.CrossRefGoogle Scholar
  199. 199.
    Keating JP, Brown BI, White NH, DiMauro S. X-linked glycogen storage disease. A cause of hypotonia, hyperuricemia, and growth retardation. Am J Dis Child. 1985;139:609–13.PubMedGoogle Scholar
  200. 200.
    Sugie H, Sugie Y, Nishida M, et al. Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency. J Child Neurol. 1989;4:95–9.PubMedCrossRefGoogle Scholar
  201. 201.
    Tonin P, Shanske S, Miranda AF, et al. Phosphogly­cerate kinase deficiency: biochemical and molecular genetic studies in a new myopathic variant (PGK Alberta). Neurology. 1993;43:387–91.PubMedCrossRefGoogle Scholar
  202. 202.
    Rosa R, George C, Fardeau M, et al. A new case of phosphoglycerate kinase deficiency: PGK Creteil associated with rhabdomyolysis and lacking hemolytic anemia. Blood. 1982;60:84–91.PubMedGoogle Scholar
  203. 203.
    Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of phosphoglycerate kinase (PGK) deficiency. Muscle Nerve. 1995;8:545–9.Google Scholar
  204. 204.
    DiMauro S, Dalakas M, Miranda AF. Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol. 1983;13:11–9.PubMedCrossRefGoogle Scholar
  205. 205.
    Fujii H, Miwa S. Other erythrocyte enzyme deficiencies associated with non-haematological symptoms: phosphoglycerate kinase and phosphofructokinase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13:141–8.PubMedCrossRefGoogle Scholar
  206. 206.
    Aasly J, van Diggelen OP, Boer AM, Bronstad G. Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms. Eur J Neurol. 2000;7:111–3.PubMedCrossRefGoogle Scholar
  207. 207.
    Toscano A, Tsujino S, Vita G, et al. Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in an Italian kindred. Muscle Nerve. 1996;19:1134–7.PubMedCrossRefGoogle Scholar
  208. 208.
    Bresolin N, Ro Y, Reyes M, et al. Muscle phosphoglycerate mutase (PGAM) deficiency: a second case. Neurology. 1983;33:1049–53.PubMedCrossRefGoogle Scholar
  209. 209.
    Tsujino S, Shanske S, Sakoda S, et al. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet. 1993;52:472–7.PubMedGoogle Scholar
  210. 210.
    Poulton KR, Khan AA, Rossi ML, Riddoch D. Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy. Funct Neurol. 1994;9:47–58.PubMedGoogle Scholar
  211. 211.
    DiMauro S, Miranda AF, Olarte M, et al. Muscle phosphoglycerate mutase deficiency. Neurology. 1982;32:584–91.PubMedCrossRefGoogle Scholar
  212. 212.
    Tsujino S, Shanske S, Sakoda S, et al. Molecular genetic studies in muscle phosphoglycerate mutase (PGAM-M) deficiency. Muscle Nerve. 1995;3:S50–3.PubMedCrossRefGoogle Scholar
  213. 213.
    DiMauro S, Miranda AF, Khan S, et al. Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy. Science. 1981;212:1277–9.PubMedCrossRefGoogle Scholar
  214. 214.
    Kanno T, Sudo K, Takeuchi I, et al. Hereditary deficiency of lactate dehydrogenase M-subunit. Clin Chim Acta. 1980;108:267–76.PubMedCrossRefGoogle Scholar
  215. 215.
    Miyajima H, Shimizu T, Kaneko E. Gene expression in lactate dehydrogenase-A subunit deficiency. Rinsho Shinkeigaku. 1992;32:1087–92.PubMedGoogle Scholar
  216. 216.
    Miyajima H, Takahashi Y, Suzuki M, et al. Molecular characterization of gene expression in human lactate dehydrogenase-A deficiency. Neurology. 1993;43:1414–9.PubMedCrossRefGoogle Scholar
  217. 217.
    Miyajima H, Takahashi Y, Kaneko E. Characterization of the oxidative metabolism in lactate dehydrogenase A deficiency. Intern Med. 1995;34:502–6.PubMedCrossRefGoogle Scholar
  218. 218.
    Miyajima H, Takahashi Y, Kaneko E. Characterization of the glycolysis in lactate dehydrogenase-A deficiency. Muscle Nerve. 1995;18:874–8.PubMedCrossRefGoogle Scholar
  219. 219.
    Takahashi Y, Miyajima H, Kaneko E. Genetic analysis of a family of lactate dehydrogenase-A subunit deficiency. Intern Med. 1995;34:326–9.PubMedCrossRefGoogle Scholar
  220. 220.
    Takahashi Y, Fujiwara S, Waki T. Hereditary lactate dehydrogenase M-subunit deficiency: lactate dehydrogenase activity in skin lesions and in hair follicles. J Am Acad Dermatol. 1991;24:339–42.CrossRefGoogle Scholar
  221. 221.
    Yoshikuni K, Tagami H, Yamada M, et al. Erythematosquamous skin lesions in hereditary lactate dehydrogenase M-subunit deficiency. Arch Dermatol. 1986;122:1420–4.PubMedCrossRefGoogle Scholar
  222. 222.
    Kanno T, Maekawa M. Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities. Muscle Nerve. 1995;3:S54–60.PubMedCrossRefGoogle Scholar
  223. 223.
    DiMauro S, DiMauro PMM. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science. 1973;182:929.PubMedCrossRefGoogle Scholar
  224. 224.
    Demaugre F, Bonnefont JP, Colonna M, et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death Physiopathological approach to carnitine palmitoyltransferase II deficiency. J Clin Invest. 1991;87:859.PubMedCrossRefGoogle Scholar
  225. 225.
    Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med. 1991;325:1862.PubMedCrossRefGoogle Scholar
  226. 226.
    Zinn AB, Zurcher VL, Krans F, et al. Carnitine palmitoyltransferase B (CPT B) deficiency: a heritable cause of neonatal cardiomyopathy and dysgenesis of the kidney. Pediatr Res. 1991;29:73A.Google Scholar
  227. 227.
    Katzir Z, Hookman B, Biro A, et al. Carnitine palmitoyltransferase deficiency: an underdiagnosed condition. Am J Nephrol. 1996;16:162–6.PubMedCrossRefGoogle Scholar
  228. 228.
    Faigel HC. Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. J Am Coll Health. 1995;44:51–4.PubMedCrossRefGoogle Scholar
  229. 229.
    Stavem K, Bjerke G, Skullerud K, Bohmer T. Rhabdomyolysis in carnitine palmitoyltransferase deficiency. Tidsskr Nor Laegeforen. 1994;114:2398–9.PubMedGoogle Scholar
  230. 230.
    Kiechl S, Kohlendorfer U, Paetzke I, et al. Myoglobinuria and palmitoyltransferase deficiency. Diagnostic procedure and differential diagnosis. Wien Klin Wochenschr. 1994;106:174–7.PubMedGoogle Scholar
  231. 231.
    Werneck LC, Boer CA, Papadimitriou A, DiMauro S. Myopathy due to carnitine palmitoyltransferase deficiency. Report of 2 cases with enzymatic analyses on muscle tissue. Arq Neuropsiquiatr. 1983;41:377–84.PubMedCrossRefGoogle Scholar
  232. 232.
    Herman J, Nadler HL. Recurrent myoglobinuria and muscle carnitine palmitoyltransferase deficiency. J Pediatr. 1977;91:247–50.PubMedCrossRefGoogle Scholar
  233. 233.
    Kieval RI, Sotrel A, Weinblatt ME. Chronic myopathy with a partial deficiency of the carnitine palmitoyltransferase enzyme. Arch Neurol. 1990;46:575–6.CrossRefGoogle Scholar
  234. 234.
    Carroll JE, Brooke MH, DeVivo DC, et al. Biochemical and physiologic consequences of carnitine palmitoyltransferase deficiency. Muscle Nerve. 1978;1:103–10.PubMedCrossRefGoogle Scholar
  235. 235.
    Layzer RB, Havel RJ, McIlroy MB. Partial deficiency of carnitine palmitoyltransferase: physiologic and biochemical consequences. Neurology. 1980;30:627–33.PubMedCrossRefGoogle Scholar
  236. 236.
    Gieron MA, Karthais JK. Carnitine palmitoyltransferase deficiency with permanent weakness. Pediatr Neurol. 1987;3:51–3.PubMedCrossRefGoogle Scholar
  237. 237.
    Wyngaarden JB, Kelley WN. Gout and hyperuricemia. New York: Grune & Stratton, Inc.; 1976. p. 111–7.Google Scholar
  238. 238.
    Sorensen LB. The pathogenesis of gout. Arch Intern Med. 1962;109:379.PubMedCrossRefGoogle Scholar
  239. 239.
    Steele TH, Boner G. Origins of the uricosuric response. J Clin Invest. 1973;52:168.CrossRefGoogle Scholar
  240. 240.
    Diamond HS, Paolino JS. Evidence for a post-secretory reabsorptive site for uric acid in man. J Clin Invest. 1973;52:1491.PubMedCrossRefGoogle Scholar
  241. 241.
    Steele TH. Urate secretion in man: the pyrazinamide suppression test. Ann Intern Med. 1973;79:734.PubMedGoogle Scholar
  242. 242.
    Rieselbach RE, Steele TH. Influence of the kidney upon urate homeostasis in health and disease. Am J Med. 1974;56:665.PubMedCrossRefGoogle Scholar
  243. 243.
    de Rougement D, Henchoz M, Roch-Rumel F. Renal urate excretion at various plasma concentrations in the rat: a free-flow micropuncture study. Am J Physiol. 1976;231:387.Google Scholar
  244. 244.
    Weinman EJ, Senekjian HO, Sansom SC, et al. Evidence for active and passive urate transport in the rat proximal tubule. Am J Physiol. 1981;240:F90.PubMedGoogle Scholar
  245. 245.
    Sorensen LB, Levinson DJ. Isolated defect in postsecretory reabsorption of uric acid. Ann Rheum Dis. 1980;39:180.PubMedCrossRefGoogle Scholar
  246. 246.
    Gibson T, Sims HP, Jiminez SA. Hypouricemia and increased renal urate clearance associated with hyperparathyroidism. Ann Rheum Dis. 1976;35:372.PubMedCrossRefGoogle Scholar
  247. 247.
    Wyngaarden JB, Kelley WN. Gout. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill, Inc; 1983. p. 1043–5.Google Scholar
  248. 248.
    Gutman AB, Yu TF. Renal function in gout: with a commentary on the renal regulation of urate excretion and the role of the kidney in the pathogenesis of gout. Am J Med. 1957;23:600.PubMedCrossRefGoogle Scholar
  249. 249.
    Simkin PA. Uric acid excretion in patients with gout. Arthritis Rheum. 1979;22:98.PubMedCrossRefGoogle Scholar
  250. 250.
    Nugent CA, MacDiarmid WD, Tyler FH. Renal excretion of urate in patients with gout. Arch Intern Med. 1964;113:115.PubMedCrossRefGoogle Scholar
  251. 251.
    Houpt JB, Ogryzlo MA. Persistence of impaired uric acid excretion in gout during reduced synthesis with allopurinol. Arthritis Rheum. 1964;7:316.Google Scholar
  252. 252.
    Snaith ML, Scott JT. Uric acid clearance in patients with gout and normal subjects. Ann Rheum Dis. 1971;30:285.PubMedCrossRefGoogle Scholar
  253. 253.
    Seegmiller JE, Grayzel AI, Howell RR, Plato C. The renal excretion of uric acid in gout. J Clin Invest. 1962;41:1094.PubMedCrossRefGoogle Scholar
  254. 254.
    Lathem W, Rodnan GP. Impairment of uric acid excretion in gout. J Clin Invest. 1962;41:1955.PubMedCrossRefGoogle Scholar
  255. 255.
    Wyngaarden JB. Gout. Adv Metab Disord. 1965;2:2.Google Scholar
  256. 256.
    Simkin PA. Urate excretion in normal and gouty men. In: Miller MM, Kaiser E, Seegmiller JE, editors. Purine metabolism in man II. New York: Plenum; 1977. p. 41.CrossRefGoogle Scholar
  257. 257.
    Yu TF, Berger L, Stone DJ, et al. Effects of pyrazinamide and pyrazinoic acid on urate clearance and other discrete renal functions. Proc Soc Exp Biol Med. 1957;96:264.PubMedGoogle Scholar
  258. 258.
    Steele TH, Reiselbach RE. The contribution of residual nephrons within the chronically diseased kidney to urate homeostasis in man. Am J Med. 1967;43:876.PubMedCrossRefGoogle Scholar
  259. 259.
    Steele TH. Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. J Lab Clin Med. 1969;74:228.Google Scholar
  260. 260.
    Suki WN, Eknoyan G, Martinez-Maldonado M. Tubular sites and mechanisms of diuretic action. Annu Rev Pharmacol. 1973;13:91.PubMedCrossRefGoogle Scholar
  261. 261.
    Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med. 1969;47:564.PubMedCrossRefGoogle Scholar
  262. 262.
    Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38:1298.PubMedCrossRefGoogle Scholar
  263. 263.
    Goldfinger S, Klinenberg JR, Seegmiller JE. Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate. N Engl J Med. 1965;272:351.PubMedCrossRefGoogle Scholar
  264. 264.
    Schulman JD, Lustberg TJ, Kennedy JL, et al. A new variant of maple syrup urine disease (branched chain ketoaciduria). Clinical and biochemical evaluation. Am J Med. 1970;49:118.PubMedCrossRefGoogle Scholar
  265. 265.
    Yu TF, Sirota JH, Berger L, et al. Effect of sodium lactate infusion on urate clearance in man. Proc Soc Exp Biol Med. 1957;96:809.PubMedGoogle Scholar
  266. 266.
    Talbott JH, Terplan KL. The kidney in gout. Medicine. 1960;39:405–62.PubMedCrossRefGoogle Scholar
  267. 267.
    Beck LH. Requiem for gouty nephropathy. Kidney Int. 1986;30:280.PubMedCrossRefGoogle Scholar
  268. 268.
    Foley RJ, Weinman EJ. Review: urate nephropathy. Am J Med Sci. 1984;288:208.PubMedCrossRefGoogle Scholar
  269. 269.
    Gudzent F. Gicht and rheumatismus. Berlin: Springer; 1928.CrossRefGoogle Scholar
  270. 270.
    Mayne JG. Pathological study of the renal lesion found in 27 patients with gout. Ann Rheum Dis. 1955;15:61.Google Scholar
  271. 271.
    Yu TF, Berger L, Dorph DJ. Renal function in gout. V. Factors influencing renal hemodynamics. Am J Med. 1979;67:766.PubMedCrossRefGoogle Scholar
  272. 272.
    Yu TF, Berger L. Renal function in gout. Its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982;72:95.PubMedCrossRefGoogle Scholar
  273. 273.
    Campbell BC, Moore MR, Goldberg A. Subclinical lead exposure: a possible cause of gout. Br Med J. 1978;2:1403.PubMedCrossRefGoogle Scholar
  274. 274.
    Batuman V, Maesaka JK, Haddad B, et al. The role of lead in gout nephropathy. N Engl J Med. 1981;304:520.PubMedCrossRefGoogle Scholar
  275. 275.
    Hall AP, Barry DP, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia; a long-term population study. Am J Med. 1967;42:27.PubMedCrossRefGoogle Scholar
  276. 276.
    Fessel WJ. Renal outcomes in gout and hyperuricemia. Am J Med. 1979;67:74.PubMedCrossRefGoogle Scholar
  277. 277.
    Fessel WJ, Barr GD. Uric acid, lean body weight, and creatinine interactions. Results from regression analyses of 78 variables. Semin Arthritis Rheum. 1970;7:115.CrossRefGoogle Scholar
  278. 278.
    Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421.PubMedCrossRefGoogle Scholar
  279. 279.
    Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605.PubMedCrossRefGoogle Scholar
  280. 280.
    Palella TD, Fox IH. Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill, Inc.; 1989. p. 971.Google Scholar
  281. 281.
    Heptinstall RH. Pathology of the kidney. Boston: Little, Brown; 1966.Google Scholar
  282. 282.
    Seegmiller JE, Frazier PD. Biochemical considerations of the renal damage of gout. Ann Rheum Dis (Suppl). 1966;25:668–72.Google Scholar
  283. 283.
    Gonick HC, Rubini ME, Gleason IO, Sommers SC. The renal lesion in gout. Ann Intern Med. 1965;62:667.PubMedGoogle Scholar
  284. 284.
    Pardo V, Perez-Stable E, Fisher ER. Ultrastructure studies in hypertension. III. Gouty nephropathy. Lab Invest. 1968;18:143.PubMedGoogle Scholar
  285. 285.
    Verger D, Leroux-Robert GP, Richet G. Depots d’urate intrarenaux chez les insuffisants renaux chroniques hyperuricemiques. Urol Nephrol. 1967;73:314.Google Scholar
  286. 286.
    Linnane JW, Burry AF, Emmerson BT. Urate deposits in the renal medulla: prevalence and associations. Nephron. 1981;27:216–22.CrossRefGoogle Scholar
  287. 287.
    Mukarami T, Kawakami H, Nakatsuda K, et al. Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria. Nephron. 1990;56:439–42.CrossRefGoogle Scholar
  288. 288.
    Farebrother DA, Pincott JR, Simmonds HA, et al. Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. J Pathol. 1981;135:159–68.PubMedCrossRefGoogle Scholar
  289. 289.
    Iwata J. Hyperuricemia in hematological disorders. Nippon Rinsho. 1996;54:3349–53.PubMedGoogle Scholar
  290. 290.
    Agha-Razii M, Amyot SL, Pichette V, et al. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol. 2000;54:59–63.PubMedGoogle Scholar
  291. 291.
    Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am J Med. 1980;68:486–91.PubMedCrossRefGoogle Scholar
  292. 292.
    Dubovsky D, Jacobs P. Acute uric acid nephropathy in thalessaemia. S Afr Med J. 1975;49:243–4.PubMedGoogle Scholar
  293. 293.
    Conger JD. Acute uric acid nephropathy. Med Clin North Am. 1990;74:859–71.PubMedGoogle Scholar
  294. 294.
    Barton JC. Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer. 1989;64:738–40.PubMedCrossRefGoogle Scholar
  295. 295.
    Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high grade non-Hodgkin’s lymphoma. Am J Med. 1993;94:133–8.PubMedCrossRefGoogle Scholar
  296. 296.
    Kjellstrand CM, Campbell DC, von Hartikch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349.PubMedCrossRefGoogle Scholar
  297. 297.
    Chastyl RC, Liu-Yin JA. Acute tumor lysis syndrome. Br J Hosp Med. 1993;49:488–92.Google Scholar
  298. 298.
    Warren DJ, Leitch AG, Leggett RJE. Hyperuricaemic acute renal failure after epileptic seizures. Lancet. 1975;2:385–7.PubMedCrossRefGoogle Scholar
  299. 299.
    Hess B, Binswanger U. Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high urine acidity. Klin Wochenschr. 1990;68: 874–9.PubMedCrossRefGoogle Scholar
  300. 300.
    Alexopoulos E, Tampakoudis P, Bili H, Mantalenakis S. Acute uric acid nephropathy in pregnancy. Obstet Gynecol. 1992;80:488–9.PubMedGoogle Scholar
  301. 301.
    Tomlinson GC, Solberg Jr LA. Acute tumor lysis syndrome with metastatic medulloblastoma. A case report. Cancer. 1984;53:1783.PubMedCrossRefGoogle Scholar
  302. 302.
    Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during turnover lysis in children with acute lymphocytic leukemia receiving Allopurinol: relationship to acute renal failure. J Pediatr. 1986;109:292.PubMedCrossRefGoogle Scholar
  303. 303.
    Albertazzi A, Cappelli P, Paolo B. Nonsteroidal anti-inflammatory drugs as risk factor for renal failure from acute uric acid nephropathy. Nephron. 1987; 46:98.PubMedCrossRefGoogle Scholar
  304. 304.
    Kelton J, Kelley WN, Holmes EW. A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med. 1978;138:612–5.PubMedCrossRefGoogle Scholar
  305. 305.
    Gabow PA. Definition and history of polycystic kidney disease. In: Watson ML, Torres VE, editors. Polycystic kidney disease. Oxford: Oxford University Press; 1996. p. 333–55.Google Scholar
  306. 306.
    Parfrey PS, Bear JC, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323:1085–90.PubMedCrossRefGoogle Scholar
  307. 307.
    Newcombe DS. Gouty arthritis and polycystic kidney disease. Ann Intern Med. 1973;79:605–6.PubMedGoogle Scholar
  308. 308.
    Martinez-Maldonado M. Polycystic kidney disease and hyperuricemia. Ann Intern Med. 1974;80:116.PubMedGoogle Scholar
  309. 309.
    Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:513.PubMedGoogle Scholar
  310. 310.
    Torres VE, Erickson SB, Smith LH, et al. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988;11:318.PubMedGoogle Scholar
  311. 311.
    Martinez-Maldonado M, Yium JJ, Eknovan G, Suki WN. Adult polycystic kidney disease: studies of the defect in urine concentration. Kidney Int. 1972;2:107.PubMedCrossRefGoogle Scholar
  312. 312.
    Gabow PA, Kaehny WB, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int. 1989;35:675–80.PubMedCrossRefGoogle Scholar
  313. 313.
    Elzinga LW, Barry JM, Torres VE, et al. Cyst decompression for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1992;2:1219.PubMedGoogle Scholar
  314. 314.
    Schwab SJ, Bander SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med. 1987;82:714–8.PubMedCrossRefGoogle Scholar
  315. 315.
    Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:250.Google Scholar
  316. 316.
    Sherstha R, McKinley C, Russ P, et al. Post menopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology. 1997; 26:1282–6.PubMedGoogle Scholar
  317. 317.
    Torres VE, Rastogi S, King BF, et al. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1186–92.PubMedGoogle Scholar
  318. 318.
    Everson GT, Scherzinger A, Berger-Leff N, et al. Polycystic liver disease: quantitation of parenchymal and cyst volume from computed tomography and clinical correlates of hepatic cysts. Hepatology. 1988;8:1627.PubMedCrossRefGoogle Scholar
  319. 319.
    Que F, Nagorney DM, Gross JB, Torres VE. Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology. 1995;108:487–94.PubMedCrossRefGoogle Scholar
  320. 320.
    Scheff RT, Zuckerman G, Harter H, et al. Diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Ann Intern Med. 1980;92:202.PubMedGoogle Scholar
  321. 321.
    Dominguez Fernandez E, Albrecht KH, Heeman U, et al. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int. 1998;11:28–31.PubMedCrossRefGoogle Scholar
  322. 322.
    Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int. 1992;41:1311.PubMedCrossRefGoogle Scholar
  323. 323.
    Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic disease at highest risk for end-stage renal disease. J Am Soc Nephrol. 1997;8:1560–7.PubMedGoogle Scholar
  324. 324.
    Reeders ST, Breuning MH, Davies ICE, et al. A highly polymorphic marker linked to adult polycystic kidney disease on chromosome 16. Nature. 1985;317:542–4.PubMedCrossRefGoogle Scholar
  325. 325.
    Gretz N, Zeier M, Geberth S, et al. Is gender a determinant for evaluation of renal failure? A study of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1989;14:178.PubMedGoogle Scholar
  326. 326.
    Leier CV, Baker PB, Kelman JW, Wooley CF. Cardiovascular abnormalities associated with autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 1987;31:203.Google Scholar
  327. 327.
    Hadimeri H, Lamm C, Nyberg G. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1998;9:8370841.Google Scholar
  328. 328.
    Chapman JR, Hilson AJW. Polycystic kidneys and abdominal aortic aneurysms. Lancet. 1980;1:646.PubMedCrossRefGoogle Scholar
  329. 329.
    Montolini J, Torras A, Revert L. Polycystic kidneys and abdominal aortic aneurysms. Lancet. 1982;1:1133.Google Scholar
  330. 330.
    Torra R, Nicolau C, Badenas C, et al. Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1996;7:2483–6.PubMedGoogle Scholar
  331. 331.
    Hossock KF, Leddy CL, Schrier RW, Gabow PA. Incidence of cardiac abnormalities associated with autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 1987;31:203.Google Scholar
  332. 332.
    Chapman AB, Johnson AM, Gabow PA. Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: how to diagnose and who to screen. Am J Kidney Dis. 1993;22:256.Google Scholar
  333. 333.
    Chapman AB, Rubinstein D, Hughes R, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med. 1992;327:916.PubMedCrossRefGoogle Scholar
  334. 334.
    Levey AS, Pauker SG, Kassirer JP. Occult intracranial aneurysms in polycystic kidney disease. N Engl J Med. 1983;308:986.PubMedCrossRefGoogle Scholar
  335. 335.
    Torres VE, Wiebers DO, Forbes GS. Cranial computed tomography and magnetic resonance imaging in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1990;1:84.PubMedGoogle Scholar
  336. 336.
    Blyth H, Ockenden BG. Polycystic disease of kidneys and liver presenting in childhood. J Med Genet. 1971;8:257.PubMedCrossRefGoogle Scholar
  337. 337.
    Cole BR, Conley SB, Stapleton FB. Polycystic kidney disease in the first year of life. J Pediatr. 1987;111:693.PubMedCrossRefGoogle Scholar
  338. 338.
    Maatoo TK, Griefer I, Geva P, Spitzer A. Acquired renal cystic disease in children and young adults on maintenance dialysis. Pediatr Nephrol. 1997;11:447–50.CrossRefGoogle Scholar
  339. 339.
    Ishikawa I. Acquired cystic disease: mechanisms and manifestations. Semin Nephrol. 1991;11:671.PubMedGoogle Scholar
  340. 340.
    Gabow PA, Kimberling WJ, Strain JD, et al. Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol. 1997;8:105–10.PubMedGoogle Scholar
  341. 341.
    Ravine D, Gibson R, Walker R, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. Lancet. 1994;343:824–7.PubMedCrossRefGoogle Scholar
  342. 342.
    Matsubara K, Susuki K, Lin YW, et al. Familial juvenile nephronophthisis in two siblings: histological findings in an early stage. Acta Paediatr Jpn. 1991;33:482.PubMedCrossRefGoogle Scholar
  343. 343.
    Sherman FE, Studnicki FM, Fetterman GH. Renal lesions of familial juvenile nephronophthisis examined by microdissection. Am J Clin Pathol. 1971;55:391.PubMedGoogle Scholar
  344. 344.
    Pascal RR. Medullary cystic disease of the kidney: study of a case with scanning and transmission electron microscopy. Am J Clin Pathol. 1973;59:659.PubMedGoogle Scholar
  345. 345.
    Zollinger HU, Mihatsch MJ, Edfonti A, et al. Nephronophthisis (medullary cystic disease of the kidney): a study using electron microscopy, immunofluorescence, and a review of the morphological findings. Helv Paediatr Acta. 1980;35:509.PubMedGoogle Scholar
  346. 346.
    Sarre H, Mertz DP. Gout secondary to renal insufficiency. Klin Wochenschr. 1965;43:1134–40.PubMedCrossRefGoogle Scholar
  347. 347.
    Richet G, Mignon F, Ardaillon R. Gout secondary to chronic renal disease. Presse Med. 1965;73:633–8.PubMedGoogle Scholar
  348. 348.
    Calabrese G, Simmonds HA, Cameron JS, Davies PM. Precocious familial gout with reduced fractional excretion of urate and normal purine enzymes. Q J Med. 1990;75:441–50.PubMedGoogle Scholar
  349. 349.
    Yokota N, Yamanaka H, Fujimoto S, et al. Autosomal dominant transmission of gouty arthritis with renal disease in a large Japanese family. Ann Rheum Dis. 1991;50:108–11.PubMedCrossRefGoogle Scholar
  350. 350.
    Duncan H, Dixon StJ. Gout, familial hyperuricaemia, and renal disease. Q J Med. 1960;29:127–36.PubMedGoogle Scholar
  351. 351.
    Rosenbloom FM, Kelley WN, Carr AA, Seegmiller JE. Familial nephropathy and gout in a kindred. Clin Res. 1967;15:270.Google Scholar
  352. 352.
    Treadwell BLJ. Juvenile gout. Ann Rheum Dis. 1971;30:279–84.PubMedCrossRefGoogle Scholar
  353. 353.
    Bennett RM, Chait A, Lewis B. Familial hyperuricaemia and hypertriglyceridaemia. Ann Rheum Dis. 1973;32:497–500.PubMedCrossRefGoogle Scholar
  354. 354.
    Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74–82.PubMedCrossRefGoogle Scholar
  355. 355.
    Thompson GR, Weiss JJ, Goldman RT, Rigg GA. Familial occurrence of hyperuricemia, gout and medullary cystic disease. Arch Intern Med. 1978;138:1614–7.PubMedCrossRefGoogle Scholar
  356. 356.
    Van Goor W, Kooiker CJ, Dorhout Mees EJ. An unusual form of renal disease associated with gout and hypertension. J Clin Pathol. 1971;24:354–9.PubMedCrossRefGoogle Scholar
  357. 357.
    Simmonds HA, Warren DJ, Cameron JS, et al. Familial gout and renal failure in young women. Clin Nephrol. 1980;14:176–82.PubMedGoogle Scholar
  358. 358.
    Cameron JS, Moro F, Simmonds HA. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol. 1993;7:105–18.PubMedCrossRefGoogle Scholar
  359. 359.
    Simmonds HA, Cameron JS, Potter CF, et al. Renal failure in young subjects with familial gout. Adv Exp Med Biol. 1980;122A:15–20.PubMedCrossRefGoogle Scholar
  360. 360.
    Massari PU, Hsu CH, Barnes RV, et al. Familial hyperuricemia and renal disease. Arch Intern Med. 1980;140:680–4.PubMedCrossRefGoogle Scholar
  361. 361.
    Richmond JM, Kincaid-Smith P, Whitworth JA, Becker GJ. Familial urate nephropathy. Clin Nephrol. 1981;16:163–8.PubMedGoogle Scholar
  362. 362.
    Leumann EP, Wegmann W. Familial nephropathy with hyperuricemia and gout. Nephron. 1983;34:51–7.PubMedCrossRefGoogle Scholar
  363. 363.
    Hollingworth P, Scott JT. Familial gout, hyperuricemia and renal impairment. Ann Rheum Dis. 1983;42 Suppl 1:87–8.CrossRefGoogle Scholar
  364. 364.
    Yarom A, Rennebohm RM, Strife F, Levinson JE. Juvenile gouty arthritis. Am J Dis Child. 1984;138:955–7.PubMedGoogle Scholar
  365. 365.
    Foreman JW, Yudkoff M. Familial hyperuricemia and renal insufficiency. Child Nephrol Urol. 1990;10:115–8.PubMedGoogle Scholar
  366. 366.
    Puig JG, Miranda ME, Mateos ML, et al. Familial nephropathy and gout: which comes first? Adv Exp Med Biol. 1991;309A:195–8.PubMedGoogle Scholar
  367. 367.
    Moro F, Ogg CS, Simmonds HA, et al. Familial juvenile gouty nephropathy with renal urate hypoexcretion preceding renal disease. Clin Nephrol. 1991;35:263–9.PubMedGoogle Scholar
  368. 368.
    McBride MB, Raman V, Ogg CS, et al. A new kindred with familial juvenile gouty nephropathy. Adv Exp Med Biol. 1991;309A:191–4.PubMedGoogle Scholar
  369. 369.
    Saeki A, Hosoya T, Okabe H, et al. Newly discovered familial juvenile gouty nephropathy in a Japanese family. Nephron. 1995;70:359–66.PubMedCrossRefGoogle Scholar
  370. 370.
    Cameron JS, Moro F, Simmonds HA. What is the pathogenesis of familial juvenile gouty nephropathy. Adv Exp Med Biol. 1991;309A:185–91.PubMedGoogle Scholar
  371. 371.
    Puig JG, Miranda ME, Mateos FA, et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med. 1993;153:357–65.PubMedCrossRefGoogle Scholar
  372. 372.
    Knorr BA, Lipkowitz MS, Potter BJ. Isolation and immunolocalization of a rat renal cortical membrane urate transporter. J Biol Chem. 1994;269:6759.PubMedGoogle Scholar
  373. 373.
    Leal-Pinto E, London RD, Knorr BA, Abramson RG. Reconstitution of hepatic uricase in planar lipid bilayer reveals a functional organic anion channel. J Membr Biol. 1995;146:123.PubMedGoogle Scholar
  374. 374.
    Leal-Pinto E, Tao W, Rappaport J, et al. Molecular cloning and functional reconstitution of a urate transporter channel. J Biol Chem. 1997;272:617.PubMedCrossRefGoogle Scholar
  375. 375.
    Isomaki H, Kreus KE. Serum and urinary uric acid in respiratory acidosis. Acta Med Scand. 1968;184:293.PubMedCrossRefGoogle Scholar
  376. 376.
    Padova J, Bendersky G. Hyperuricemia in diabetic ketoacidosis. N Engl J Med. 1962;267:530.PubMedCrossRefGoogle Scholar
  377. 377.
    Manual MA, Steele TH. Changes in renal urate handling after prolonged thiazide treatment. Am J Med. 1974;57:741.CrossRefGoogle Scholar
  378. 378.
    Demartini FE. Hyperuricemia induced by drugs. Arthritis Rheum. 1965;8:823.PubMedCrossRefGoogle Scholar
  379. 379.
    Stewart RJ, Chonko AM. Pharmacologic inhibition of urate transport across perfused and non-perfused rabbit proximal straight tubules. Kidney Int. 1981;19:258.Google Scholar
  380. 380.
    Cutler RE, Kleeman CR, Maxwell MH, et al. Physiologic studies in nephrogenic diabetes insipidus. J Clin Endocrinol Metab. 1962;22:827–38.PubMedCrossRefGoogle Scholar
  381. 381.
    Gorden P, Robertson GL, Seegmiller JE. Hyperuri­cemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult. Studies of uric acid metabolism and plasma vasopressin. N Engl J Med. 1971;284:1057–60.PubMedCrossRefGoogle Scholar
  382. 382.
    Mizuno O. Transient nephrogenic diabetes insipidus associated with acute hepatic failure in pregnancy. Endocrinol Jpn. 1987;34:449–55.PubMedCrossRefGoogle Scholar
  383. 383.
    Harper M, Hatjis CG, Appel RG, Austin WE. Vasopressin-resistant diabetes insipidus, liver dysfunction, hyperuricemia and decreased renal function. A case report. J Reprod Med. 1987;32:862–5.PubMedGoogle Scholar
  384. 384.
    Yokoyoshi Y, Saito S. Abnormal serum uric acid level in endocrine disorders. Nippon Rinsho. 1996;54:3360–3.Google Scholar
  385. 385.
    Decaux G, Prospert F, Namias B, Soupart A. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia. Am J Med. 1997;103:376–82.PubMedCrossRefGoogle Scholar
  386. 386.
    Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am. 1995;24:549–72.PubMedGoogle Scholar
  387. 387.
    van Lieburg AF, Knoers NV, Monnens LA. Clinical presentations and follow-up of 30 patients with congenital diabetes insipidus. J Am Soc Nephrol. 1999;10:1958–64.PubMedGoogle Scholar
  388. 388.
    Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis. Nephron. 1993;65:346–9.PubMedCrossRefGoogle Scholar
  389. 389.
    Carter C, Simpkiss M. The “carrier” state in nephrogenic diabetes insipidus. Lancet. 1956;2:1069–73.CrossRefGoogle Scholar
  390. 390.
    van Lieburg AF, Verrdijk MA, Schoute F, et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterogeneous for a vasopressin type 2 receptor mutation. Hum Genet. 1995;96:70–8.PubMedCrossRefGoogle Scholar
  391. 391.
    Nicholas HO. Urinary calculi. III. Further observations on calculi from patients in the southeast Texas area. Clin Chem. 1961;7:175–7.PubMedGoogle Scholar
  392. 392.
    Leonard RH. Quantitative composition of kidney stones. Clin Chem. 1961;7:546–51.PubMedGoogle Scholar
  393. 393.
    Hughes J, Coppridge WM, Roberts LC, Mann VI. Oxalate urinary tract stones. JAMA. 1960;172:774–6.CrossRefGoogle Scholar
  394. 394.
    Prien EL. Crystallographic analysis of urinary calculi; a 25 year survey study. J Urol. 1963;89:917–24.PubMedGoogle Scholar
  395. 395.
    Melick RA, Henneman PH. Clinical and laboratory studies of 207 consecutive patients in a kidney stone clinic. N Engl J Med. 1958;259:307–14.PubMedCrossRefGoogle Scholar
  396. 396.
    Herring LC. Observations on the analysis of 10,000 urinary calculi. J Urol. 1962;88:545–62.PubMedGoogle Scholar
  397. 397.
    Yu TF. Uric acid nephrolithiasis. Handb Exp Pharmacol. 1978;51:397–422.CrossRefGoogle Scholar
  398. 398.
    Halabe A, Sperling O. Uric acid nephrolithiasis. Miner Electrolyte Metab. 1994;20:424–31.PubMedGoogle Scholar
  399. 399.
    Harrache D, Mesai A, Addou A, et al. Urolithiasis in children in West Algeria. Ann Urol (Paris). 1997;31:84.Google Scholar
  400. 400.
    Borghi L, Meschi T, Amato F, et al. Hot occupation and nephrolithiasis. J Urol. 1993;150:1757.PubMedGoogle Scholar
  401. 401.
    Gutman AB, Yu TF. Urinary ammonium excretion in primary gout. J Clin Invest. 1965;44:1474–81.PubMedCrossRefGoogle Scholar
  402. 402.
    Henneman PH, Wallach S, Dempsey EF. The metabolic defect responsible for uric acid stone formation. J Clin Invest. 1962;41:537–42.PubMedCrossRefGoogle Scholar
  403. 403.
    Woeber KA, Ricca L, Hills AG. Pathogenesis of uric acid urolithiasis. Clin Res. 1962;10:45.Google Scholar
  404. 404.
    Gutman AB, Yu TF. An abnormality of glutamine metabolism in primary gout. Am J Med. 1963;35:820–31.PubMedCrossRefGoogle Scholar
  405. 405.
    Clarke AM, McKenzie RG. Ileostomy and the risk of urinary uric acid stones. Lancet. 1969;2:395–7.PubMedCrossRefGoogle Scholar
  406. 406.
    Gigax JH, Leach JR. Uric acid calculi associated with ileostomy for ulcerative colitis. J Urol. 1971;105:797–9.Google Scholar
  407. 407.
    Yu TF, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67:1133–48.PubMedGoogle Scholar
  408. 408.
    Sperling O, Eilam G, Persky-Brosh S, DeVries A. Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis: a familial abnormality associated with excessive uric acid production and gout. Biochem Med. 1972;6:310.PubMedCrossRefGoogle Scholar
  409. 409.
    DeVries A, Sperling O. Familial gouty malignant uric acid lithiasis due to mutant phosphoribosylpyrophosphate synthetase. Urologie A. 1973;12:153.Google Scholar
  410. 410.
    Kelley WN, Wyngaarden JB. Clinical syndromes associated with hypoxanthine-guanine phosphoribosyltransferase deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited diseases. New York: McGraw-Hill, Inc.; 1983. p. 1115.Google Scholar
  411. 411.
    Michener WM. Hyperuricemia and mental retardation with athetosis and self-mutilation. Am J Dis Child. 1967;113:155.Google Scholar
  412. 412.
    Nyhan WL. The Lesch-Nyhan syndrome. Annu Rev Med. 1973;24:41.PubMedCrossRefGoogle Scholar
  413. 413.
    Cameron JS, Simmonds HA, Webster DR, et al. Problems of diagnosis in an adolescent with hypoxanthine guanine phosphoribosyltransferase deficiency. Adv Exp Med Biol. 1984;165A:7–13.CrossRefGoogle Scholar
  414. 414.
    Stone TW, Simmonds HA. Purines: basic and clinical aspects. London: Kluwer; 1991.CrossRefGoogle Scholar
  415. 415.
    Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol. 1983;130:157–9.PubMedGoogle Scholar
  416. 416.
    Kenney IJ. Renal sonography in long standing Lesch-Nyhan syndrome. Clin Radiol. 1991;43:39–41.PubMedCrossRefGoogle Scholar
  417. 417.
    Grampsas SA, Chandhoke PS, Fan J, et al. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36:53.PubMedCrossRefGoogle Scholar
  418. 418.
    Dimitrakov D, Simeonov S. Studies on nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Folia Med (Plovdiv). 1994;36:27.Google Scholar
  419. 419.
    Ng CS, Yost A, Streem SB. Nephrolithiasis with autosomal dominant polycystic kidney disease: contemporary urological management. J Urol. 2000;163:726.PubMedCrossRefGoogle Scholar
  420. 420.
    Steg A, Aboulker P, Reziciner S, Bernard E. The association of polycystic kidney and uric acid lithiasis. Ann Med Intern (Paris). 1970;121:431.Google Scholar
  421. 421.
    Chen YT. Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol. 1991;5:71–6.PubMedCrossRefGoogle Scholar
  422. 422.
    Chen YT, Van Hove JL. Renal involvement in type I glycogen storage disease. Adv Nephrol Necker Hosp. 1995;24:357–65.PubMedGoogle Scholar
  423. 423.
    Howell RR. The interrelationship of glycogen storage disease and gout. Arthritis Rheum. 1965;8:780.PubMedCrossRefGoogle Scholar
  424. 424.
    Howell RR, Ashton DM, Wyngaarden JB. Glucose-6-phosphatase deficiency glycogen storage disease. Studies on the interrelationship of carbohydrate, lipid and purine abnormalities. Pediatrics. 1982;29:553.Google Scholar
  425. 425.
    Kelley WM, Rosenbloom FM, Seegmiller JE, Howell RR. Excessive production of uric acid in type I glycogen storage disease. J Pediatr. 1968;72:488.PubMedCrossRefGoogle Scholar
  426. 426.
    Evans WP, Resnick MJ, Boyce WH. Homozygous cystinuria – evaluation of 35 patients. J Urol. 1982;127:707.PubMedGoogle Scholar
  427. 427.
    Resnick MJ, Goodman HO, Boyce WH. Heterozygous cystinuria and calcium oxalate nephrolithiasis. J Urol. 1979;122:52.PubMedGoogle Scholar
  428. 428.
    King Jr JS, Wainer A. Cystinuria with hyperuricemia and methioninuria. Biochemical study of a case. Am J Med. 1967;43:125–30.PubMedCrossRefGoogle Scholar
  429. 429.
    Krizek V. Uricemia in cystinuria. Horm Metab Res. 1972;4:51–8.PubMedCrossRefGoogle Scholar
  430. 430.
    Meloni CR, Canary JJ. Cystinuria with hyperuricemia. JAMA. 1967;200:257–9.PubMedCrossRefGoogle Scholar
  431. 431.
    Vergis JG, Walker AR. Cystinuria, hyperuricemia and uric acid nephrolithiasis: case report. Nephron. 1970;7:577–9.PubMedCrossRefGoogle Scholar
  432. 432.
    Gutman AB, Yu TF. Uric acid nephrolithiasis. Am J Med. 1968;45:756–79.PubMedCrossRefGoogle Scholar
  433. 433.
    Wells RG, Hediger MA. Cloning of a rat kidney cDNA that stimulates dibasic acid neutral amino acid transport and has sequence similarity to glucosidases. Proc Natl Acad Sci USA. 1992;89:5596–600.PubMedCrossRefGoogle Scholar
  434. 434.
    Lee WS, Wells RG, Subbog RV, et al. Cloning and chromosomal localization of a human kidney cDNA involved in cystine, dibasic, and neutral amino acid transport. J Clin Invest. 1993;91:1959–63.PubMedCrossRefGoogle Scholar
  435. 435.
    Pras E, Arber N, Aksentijevich I, et al. Localization of a gene causing cystinuria to chromosome 2p. Nat Genet. 1995;56:1297–303.Google Scholar
  436. 436.
    Wartenfeld R, Golomb E, Katz G, et al. Molecular analysis of cystinuria in Libyan Jews: exclusion of the SLC3A1 gene and mapping of a new locus on 19q. Am J Hum Genet. 1997;60:617–24.PubMedGoogle Scholar
  437. 437.
    Bisceglia L, Calonge MJ, Totaro A, et al. Localization, by linkage analysis, of the cystinuria type III gene to chromosome 19q13.1. Am J Hum Genet. 1997;60:611–6.PubMedGoogle Scholar
  438. 438.
    Sakhaee K, Poindexter JR, Pak CYC. The spectrum of metabolic abnormalities in patients with cystine nephrolithiasis. J Urol. 1989;141:819–21.PubMedGoogle Scholar
  439. 439.
    de Vries A, Frank M, Atsmon A. Inherited uric acid lithiasis. Am J Med. 1962;33:880–92.PubMedCrossRefGoogle Scholar
  440. 440.
    Greene ML, Marcus R, Aurbach GD, et al. Hypouricemia due to isolated renal tubular defect. Am J Med. 1972;53:361.PubMedCrossRefGoogle Scholar
  441. 441.
    Benjamin D, Sperling O, Weinberger A, et al. Familial hypouricemia due to isolated renal tubular defect. Nephron. 1977;18:220.PubMedCrossRefGoogle Scholar
  442. 442.
    Tachibana S, Wakatsuki A, Kamei O, et al. A case of idiopathic hypouricemia with recurrent renal stones. Nish J Urol. 1982;44:795.Google Scholar
  443. 443.
    Hedley JM, Phillips PJ. Familial hypouricemia and uric acid calculi. Case report. J Clin Pathol. 1980;33:971.PubMedCrossRefGoogle Scholar
  444. 444.
    Frank M, Many M, Sperling O. Familial renal hypouricemia: two additional cases with uric acid lithiasis. Br J Urol. 1979;51:88.PubMedCrossRefGoogle Scholar
  445. 445.
    Gaspar GA, Puig TG, Mateos FA, et al. Hypouricemia due to renal urate wasting: different types of tubular transport defects. Adv Exp Med Biol. 1986;195A:357.CrossRefGoogle Scholar
  446. 446.
    Pak CYC, Kaplan RA, Bone H, et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciuria. N Engl J Med. 1975;292:497–500.PubMedCrossRefGoogle Scholar
  447. 447.
    Sperling O, Weinberger A, Oliver I, et al. Hypouricemia, hypercalciuria and decreased bone density: a hereditary syndrome. Ann Intern Med. 1974;80:482.PubMedGoogle Scholar
  448. 448.
    Weitz R, Sperling O. Hereditary renal hypouricemia: Isolated tubular defect of urate reabsorption. J Pediatr. 1980;96:850.PubMedCrossRefGoogle Scholar
  449. 449.
    Takeda E, Kuroda T, Ito M, et al. Hereditary renal hypouricemia in children. J Pediatr. 1985;107:71.PubMedCrossRefGoogle Scholar
  450. 450.
    Ishikawa I, Sakurai Y, Maasuzaki S, et al. Exercise-induced acute renal failure in 3 patients with renal hypouricemia. Jpn J Nephrol. 1990;32:923.Google Scholar
  451. 451.
    Erley CMM, Hirschberg RR, Hoefer W, Schaefer K. Acute renal failure due to uric acid nephropathy in a patient with renal hypouricemia. Klin Wochenschr. 1989;67:308.PubMedCrossRefGoogle Scholar
  452. 452.
    Dwash IL, Roncari DAK, Marliss E, Fox IH. Hypouricemia in disease: a study of different mechanisms. J Lab Clin Med. 1977;90:153.Google Scholar
  453. 453.
    Ramsdell C, Kelley WN. The clinical significance of hypouricemia. Ann Intern Med. 1973;78:239–42.PubMedGoogle Scholar
  454. 454.
    Wyngaarden JB. The use and interpretation of laboratory derived data. In: Beeson PB, McDermott W, editors. Textbook of medicine. Philadelphia: Saunders; 1975. p. 1880.Google Scholar
  455. 455.
    Mikkelsen WM, Dodge HJ, Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan, 1959–1960. Am J Med. 1965;39:242–51.PubMedCrossRefGoogle Scholar
  456. 456.
    Tofuku Y, Ito M, Takasaki H, et al. A case of familial renal hypouricemia associated with acute renal failure. Purine Pyrimidine Metab (Jpn). 1990;14:8.Google Scholar
  457. 457.
    Gafter U, Zuta A, Frydman M, et al. Hypouricemia due to familial isolated renal tubular uricosuria – evaluation with combined pyrazinamide-probenecid test. Miner Electrolyte Metab. 1989;15:309.PubMedGoogle Scholar
  458. 458.
    Histome I, Ogino K, Saito M, et al. Renal hypouricemia due to an isolated renal defect of urate transport. Nephron. 1988;49:81.CrossRefGoogle Scholar
  459. 459.
    Matsuda O, Shiigai T, Ito Y, et al. A case of familial renal hypouricemia associated with increased secretion of PAH and idiopathic edema. Nephron. 1982;30:178.PubMedCrossRefGoogle Scholar
  460. 460.
    Fujiwara J, Takamitsue J, Ueda N, et al. Hypouricemia due to an isolated defect in renal tubular urate reabsorption. Clin Nephrol. 1980;13:44.PubMedGoogle Scholar
  461. 461.
    Delexelle F, Trombert JC, Bouvier MF, Canarelli G. Idiopathic renal hypouricemia I. Observation. Presse Med. 1980;35:2578.Google Scholar
  462. 462.
    Akaoka I, Nishizawa T, Yano E, et al. Renal urate excretion in five cases of hypouricemia with an isolated renal defect of urate transport. J Rheumatol. 1977;4:86.PubMedGoogle Scholar
  463. 463.
    Shichiri M, Iwamoto H, Maeda M, et al. Hypouricemia due to subtotal defect in the urate transport. Clin Nephrol. 1987;28:300.PubMedGoogle Scholar
  464. 464.
    Nakajima H, Gomi M, Iida S, et al. Familial renal hypouricemia with intact reabsorption of uric acid. Nephron. 1987;45:40.PubMedCrossRefGoogle Scholar
  465. 465.
    Gutman AB, Yu TF. A three-component system for regulations of renal excretion of uric acid in man. Trans Assoc Am Physicians. 1961;74:353.PubMedGoogle Scholar
  466. 466.
    Mudge GH. Uricosuric action of cholecystographic agents. N Engl J Med. 1971;284:929–33.PubMedCrossRefGoogle Scholar
  467. 467.
    Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. Ann Intern Med. 1971;74:845–52.PubMedGoogle Scholar
  468. 468.
    Ramsdell CM, Postlethwaite AE, Kelley WN. Uricosuric effect of glyceryl guaiacolate. J Rheum. 1974;1:114–6.PubMedGoogle Scholar
  469. 469.
    Gross JM. Fanconi syndrome (adult type) developing secondary to the ingestion of outdated tetracycline. Ann Intern Med. 1963;48:523.Google Scholar
  470. 470.
    Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of uP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333.PubMedCrossRefGoogle Scholar
  471. 471.
    Roch-Ramel F, Guisan B. Effect of uricosuric drugs and pyrazinoate on urate uptake by human brush-border membrane vesicles. Eperientia. 1995;51:A93.Google Scholar
  472. 472.
    Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol. 1994;266:F797.PubMedGoogle Scholar
  473. 473.
    Burnier M, Rutshmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339.PubMedCrossRefGoogle Scholar
  474. 474.
    Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens. 1994;7:1035.PubMedGoogle Scholar
  475. 475.
    Dickinson CJ, Smellie JM. Xanthinuria. Br Med J. 1959;2:1217.PubMedCrossRefGoogle Scholar
  476. 476.
    Srivastava RN, Hussainy MAA, Goel RO, Rose GA. Bladder stone disease in children in Afghanistan. Br J Urol. 1986;58:374.PubMedCrossRefGoogle Scholar
  477. 477.
    Kenawi MM. Xanthinuria and xanthine calculous pyonephrosis. J R Coll Surg Edinb. 1976;21:95.PubMedGoogle Scholar
  478. 478.
    De Vries A, Sperling O. Implications of purine metabolism for the kidney and urinary tract. Ciba Found Symp. 1977;48:179.PubMedGoogle Scholar
  479. 479.
    Carpenter TO, Lebowitz RL, Nelson D, Bauer S. Hereditary xanthinuria presenting in infancy with nephrolithiasis. J Pediatr. 1986;109:307.PubMedCrossRefGoogle Scholar
  480. 480.
    Henderson MJ, Bradbury M, Brocklebank JT, Simmonds HA. Xanthinuria: presentation with acute renal failure in a nine month old girl. J Inherit Metab Dis. 1992;15:302.Google Scholar
  481. 481.
    Maynard J, Benson P. Hereditary xanthinuria in 2 Pakistani sisters: asymptomatic in one with β-thalassemia but causing xanthine stone, obstructive uropathy and hypertension in the other. J Urol. 1988;139:338.PubMedGoogle Scholar
  482. 482.
    Fildes RD. Hereditary xanthinuria with severe urolithiasis occurring in infancy as renal tubular acidosis and hypercalciuria. J Pediatr. 1989;115:277.PubMedCrossRefGoogle Scholar
  483. 483.
    Dent CE, Philpot GR. Xanthinuria, an inborn error (or deviation) of metabolism. Lancet. 1954;1:182.CrossRefGoogle Scholar
  484. 484.
    Salti IS, Mouradian M, Frayha RA. Hereditary xanthinuria. Arab J Med. 1982;1:5.Google Scholar
  485. 485.
    Simmonds HA, Stutchbury JH, Webster DR, et al. Pregnancy in xanthinuria: demonstration of fetal uric acid production? J Inherit Metab Dis. 1984;7:77.PubMedCrossRefGoogle Scholar
  486. 486.
    Dwosh IL, Roncari DAK, Marliss E, Fox IH. Hypouricemia in disease: a study of different mechanisms. J Lab Clin Med. 1977;90:153.PubMedGoogle Scholar
  487. 487.
    Frezal J, Malassenet R, Cartier P, et al. Sur un cas de xanthinurie. Arch Fr Pediatr. 1967;24:129.PubMedGoogle Scholar
  488. 488.
    Cifuentes-Delatte L, Castro-Mendoza HJ. Xanthinuria familiar. Rev Clin Esp. 1967;107:244.PubMedGoogle Scholar
  489. 489.
    Kennedy JH, Semmence AM. Xanthinuria: a new case. Clin Chem. 1980;26:1758.PubMedGoogle Scholar
  490. 490.
    Rodriguez GF, Servan PR, Rodriguez JP. Un nuevo caso de xanthinuria. Asociacion con SIDA. Ann Intern Med (Madrid). 1989;6:219.Google Scholar
  491. 491.
    Delbarre F, Weissenbach R, Auscher C, De Gery A. Acess de gout chez xanthinurique. Nouv Presse Med. 1973;2:2465.PubMedGoogle Scholar
  492. 492.
    Wilson DM, Topia HR. Xanthinuria in a large kindred. Adv Exp Med Biol. 1974;41A:343.CrossRefGoogle Scholar
  493. 493.
    Isaacs H, Heffron JJA, Berman L, et al. Xanthine, hypoxanthine and muscle pain. Histochemical and biochemical observations. S Afr Med J. 1975;49:1035.PubMedGoogle Scholar
  494. 494.
    De Vooght HJ, Von de Kamp JJP, Van Gerderen HH, et al. Een xanthinsteen by een kind met xanthinuie: Enkele beschonasingen over een Zeldaure “inborn error of metabolism”. Ned Tijdschr Geneeskd. 1973;117:976.Google Scholar
  495. 495.
    Engleman K, Watts RWE, Klinenberg JR, et al. Clinical, physiological and biochemical studies of a patient with xanthinuria and pheochromocytoma. Am J Med. 1964;37:839–61.CrossRefGoogle Scholar
  496. 496.
    Parker R, Snedden W, Watts RWE. The quantitative determination of hypoxanthine and xanthine (“oxypurines”) in skeletal muscle from two patients with congenital xanthine oxidase deficiency (xanthinuria). Biochem J. 1970;116:317.PubMedGoogle Scholar
  497. 497.
    Chalmers RA, Johnson M, Pallis C, Watts RWE. Xanthinuria with myopathy (with some observations on the renal handling of oxypurines in the disease). Q J Med. 1969;38:493.PubMedGoogle Scholar
  498. 498.
    Simmonds HA, Cameron JS, Barrat TM, et al. Purine enzyme defects as a cause of acute renal failure in childhood. Pediatr Nephrol. 1989;3:433.PubMedCrossRefGoogle Scholar
  499. 499.
    Wada Y, Nishimura Y, Tanabu M, et al. Hypouricemic, mentally retarded infant with a defect of 5-phosphoribosyl-1-pyrophosphate synthetase of erythrocytes. Tohoku J Exp Med. 1974;113:149–57.PubMedCrossRefGoogle Scholar
  500. 500.
    Inuma K, Wada Y, Onuma A, Tanabu M. Electroencephalographic study of an infant with phosphoribosylpyrophosphate synthetase deficiency. Tohoku J Exp Med. 1975;116:53–5.PubMedCrossRefGoogle Scholar
  501. 501.
    Imaeda H, Wada Y. PRPP synthetase deficiency. Ryoikibetsu Shokogun Shirizu. 1998;18:435–7.PubMedGoogle Scholar
  502. 502.
    Wilson DB, Goldstein NP. Renal urate excretion in patients with Wilson’s disease. Kidney Int. 1973;4:331.PubMedCrossRefGoogle Scholar
  503. 503.
    Leu MI, Strickland GT, Gutman AB. Renal function in Wilson’s disease: response to penicillamine therapy. Am J Med Sci. 1970;250:381.CrossRefGoogle Scholar
  504. 504.
    Morgan HG, Steewart WK, Lowe KG, et al. Wilson’s disease and the Fanconi syndrome. Q J Med. 1962;31:361.PubMedGoogle Scholar
  505. 505.
    Elsas LJ, Hayslett JP, Spargo BH, et al. Wilson’s disease with reversible renal tubular function. Ann Intern Med. 1971;75:127.Google Scholar
  506. 506.
    Cusworth DC, Dent CE, Flynn FV. The amino-aciduria in galactosaemia. Arch Dis Child. 1955;30:150.PubMedCrossRefGoogle Scholar
  507. 507.
    Lamiere N, Mussche M, Baele G, et al. Hereditary fructose intolerance: a difficult diagnosis in the adult. Am J Med. 1978;65:416.CrossRefGoogle Scholar
  508. 508.
    Schneider JA, Schulman JD, Seegmiller JE. Cystinosis and the Fanconi syndrome. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The metabolic basis of inherited disease. 4th ed. New York: McGraw-Hill, Inc; 1978. p. 1660.Google Scholar
  509. 509.
    Levy HL. Hartnup disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc.; 1995. p. 3629.Google Scholar
  510. 510.
    Bennett JS, Bond J, Singer I, Gottlieb AJ. Hypouricemia in Hodgkin’s disease. Ann Intern Med. 1972;76:751.PubMedGoogle Scholar
  511. 511.
    Tykarski A. Mechanism of hypouricemia in Hodgkin’s disease. Isolated defect in postsecretory reabsorption of uric acid. Nephron. 1988;50:217.PubMedCrossRefGoogle Scholar
  512. 512.
    Weinstein B, Irreverre F, Watkins DM. Lung carcinoma, hypouricemia and aminoaciduria. Am J Med. 1965;39:520.PubMedCrossRefGoogle Scholar
  513. 513.
    Gorshein D, Asbell S. Ectopic production of hormones in tumors. JAMA. 1976;235:2716.PubMedCrossRefGoogle Scholar
  514. 514.
    Cooper DS. Oat-cell carcinoma and severe hypouricemia. N Engl J Med. 1973;288:321.PubMedCrossRefGoogle Scholar
  515. 515.
    Smithline N, Kassirer JP, Cohen JJ. Light-chain nephropathy. N Engl J Med. 1976;294:71.PubMedCrossRefGoogle Scholar
  516. 516.
    Beck IH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1979;301:528.PubMedCrossRefGoogle Scholar
  517. 517.
    Weinberger A, Santo M, Shalit M, et al. Abnormality in renal urate handling in the syndrome of inappropriate secretion of antidiuretic hormone. Isr J Med Sci. 1982;18:711.PubMedGoogle Scholar
  518. 518.
    Osterlind K, Hansen M, Dombernowsky P. Hypouricemia and inappropriate secretion of antidiuretic hormone in small cell bronchogenic carcinoma. Acta Med Scand. 1981;209:289.PubMedCrossRefGoogle Scholar
  519. 519.
    Kay NE, Gottlieb AJ. Hypouricemia in Hodgkin’s disease. Cancer. 1973;32:1508–11.PubMedCrossRefGoogle Scholar
  520. 520.
    Chisholm Jr JJ, Harrison HC, Everlein WR, Harrison HE. Amino-aciduria, hypophosphatemia and rickets in lead poisoning. Am J Dis Child. 1955;89:159.Google Scholar
  521. 521.
    Clarkson TW, Keneh JE. Urinary excretion of amino acids by men absorbing heavy metals. Biochem J. 1965;62:361.Google Scholar
  522. 522.
    Michelis MF, Warms PC, Fusco RD, Davis BB. Hypouricemia and hyperuricosuria in Laennec cirrhosis. Arch Intern Med. 1974;134:681.PubMedCrossRefGoogle Scholar
  523. 523.
    Schlosstein L, Kippen I, Bluestone R, et al. Association between hypouricemia and jaundice. Ann Rheum Dis. 1974;33:308.PubMedCrossRefGoogle Scholar
  524. 524.
    Pui CH, Roy 3rd S, Noe HN. Urolithiasis in childhood acute leukemia and non-Hodgkin’s lymphoma. J Urol. 1986;136:1052.PubMedGoogle Scholar
  525. 525.
    Pochedly C. Hyperuricemia in leukemia and lymphoma. I. Clinical findings and pathophysiology. N Y State J Med. 1973;73:1085.PubMedGoogle Scholar
  526. 526.
    Moe PJ. Formation of urinary calculi and uric acid findings in children with leukemia. Tidsskr Nor Laegeforen. 1970;90:1201.PubMedGoogle Scholar
  527. 527.
    Teluk J, Reiszkowski J. Case of chronic myeloid leukemia complicated by nephrolithiasis. Wiad Lek. 1976;29:1577.PubMedGoogle Scholar
  528. 528.
    Hsu AC, Kooh SW, Izukawa T, Fox IH. Uric acid lithiasis in an infant with cyanotic congenital heart disease. J Pediatr. 1977;91:1021.PubMedCrossRefGoogle Scholar
  529. 529.
    Yu TF. Review article. Urolithiasis in hyperuricemia and gout. J Urol. 1981;126:424.PubMedGoogle Scholar
  530. 530.
    Lynch EC. Uric acid metabolism in proliferative ­diseases of the marrow. Arch Intern Med. 1962;109:639.PubMedCrossRefGoogle Scholar
  531. 531.
    Lancina Martin JA, Garcia Buitron JM, Diaz Bermudez J, et al. Urinary lithiasis in transplanted kidney. Arch Esp Urol. 1997;50:141.PubMedGoogle Scholar
  532. 532.
    Norlen BJ, Hellstrom M, Nisa M, Robertson WG. Uric acid stone formation in a patient after kidney transplantation – metabolic and therapeutic considerations. Scand J Urol Nephrol. 1995;29:335.PubMedCrossRefGoogle Scholar
  533. 533.
    Cantarell MC, Capdevila L, Morlens M, Piera L. Uric acid calculus in renal transplant patients treated with cyclosporine. Clin Nephrol. 1991;35:288.PubMedGoogle Scholar
  534. 534.
    Harper JM, Samuell CT, Hallson PC, et al. Risk factors for calculus formation in patients with renal transplants. Br J Urol. 1994;74:147.PubMedCrossRefGoogle Scholar
  535. 535.
    Glicklich D, Gruber HE, Matas AJ, et al. 2,8-Dihydroxyadenine urolithiasis: report of a case first diagnosed after renal transplant. Q J Med. 1988;68:785.PubMedGoogle Scholar
  536. 536.
    Adam O, Goebel FD. Secondary gout and pseudo-Bartter syndrome in females with laxative abuse. Klin Wochenschr. 1987;65:833.PubMedCrossRefGoogle Scholar
  537. 537.
    Dick WH, Lingeman JE, Preminger JE, et al. Laxative abuse as a cause for ammonium urate calculi. J Urol. 1990;143:244.PubMedGoogle Scholar
  538. 538.
    Asanuma H, Nagatsuma K, Baba S, Murai M. A case of Prader-Willi syndrome accompanied with a renal stone. Hinyokika Kiyo. 1998;44:37.PubMedGoogle Scholar
  539. 539.
    Cassidy SB. Prader-Willi syndrome. Curr Probl Pediatr. 1984;14:1.PubMedGoogle Scholar
  540. 540.
    Holm VJ, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;912:398.Google Scholar
  541. 541.
    Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet. 1990;35:319.PubMedCrossRefGoogle Scholar
  542. 542.
    Leistenschneider W, Nagel R. Experiences with lavage cytology from renal pelvis and ureter. Urologe A. 1977;16:230.PubMedGoogle Scholar
  543. 543.
    Dean TE, Harrison NW, Bishop NL. CT scanning in the diagnosis and management of radiolucent urinary calculi. Br J Urol. 1988;62:405.PubMedCrossRefGoogle Scholar
  544. 544.
    Nakada SY, Hoff DG, Attai S, et al. Determination of stone composition by noncontrast spiral computed tomography in the clinical setting. Urology. 2000;55:816.PubMedCrossRefGoogle Scholar
  545. 545.
    Band PR, Silverberg DS, Henderson JF. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283:354–7.PubMedCrossRefGoogle Scholar
  546. 546.
    Ogawa A, Watanabe K, Minejima N. Renal xanthine stones in Lesch-Nyhan syndrome treated with allopurinol. Urology. 1985;26:56.PubMedCrossRefGoogle Scholar
  547. 547.
    Stevens SK, Parker BR. Renal oxypurine deposition in Lesch-Nyhan syndrome: sonographic evaluation. Pediatr Radiol. 1989;19:479.PubMedCrossRefGoogle Scholar
  548. 548.
    Ablin A, Stephens BG, Hirata T, et al. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt’s lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972;21:771–8.PubMedCrossRefGoogle Scholar
  549. 549.
    Klinenberg JR, Goldfinger S, Miller J, et al. The effectiveness of a xanthine oxidase inhibitor in the treatment of gout. Arthritis Rheum. 1963;6:779–80.Google Scholar
  550. 550.
    Klinenberg JR, Goldfinger SF, Seegmiller JE. The effectiveness of xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med. 1965;62:639–47.PubMedGoogle Scholar
  551. 551.
    Sorensen LB. Seminars on the Lesch-Nyhan syndrome: management and treatment. Discussion. Fed Proc. 1968;27:1097.Google Scholar
  552. 552.
    Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones – a rare complication of allopurinol therapy. N Engl J Med. 1969;280:426.PubMedCrossRefGoogle Scholar
  553. 553.
    Mizuno T, Segawa M, Kurumada T. Clinical and therapeutic aspects of the Lesch-Nyhan syndrome in Japanese children. Neuropaediatrie. 1970;2:38.CrossRefGoogle Scholar
  554. 554.
    Manzke H. Xanthine stone formation subsequent to allopurinol therapy. Dtsch Med Wochenschr. 1974;99:918.Google Scholar
  555. 555.
    Wyngaarden JB. Allopurinol and xanthine nephropathy. N Engl J Med. 1970;283:371–2.PubMedCrossRefGoogle Scholar
  556. 556.
    Sperling O, Brosh S, Boer P, et al. Urinary xanthine stones in an allopurinol treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Israel J Med Sci. 1978;14:288.PubMedGoogle Scholar
  557. 557.
    Rundles RW, Wyngaarden JB, Hitchings G, et al. Effects of xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout. Trans Assoc Am Physicians. 1963;76:126–40.Google Scholar
  558. 558.
    Yu TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo (3,4-d)-pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med. 1964;37:885–98.CrossRefGoogle Scholar
  559. 559.
    Segal S, Wyngaarden JB. Plasma glutamine and oxypurine content in patients with gout. Proc Soc Exp Biol Med. 1955;88:342–5.PubMedGoogle Scholar
  560. 560.
    Jorgensen S. Hypoxanthine and xanthine accumulated in stored human blood: determination of relative amounts by spectrophotometry. Acta Pharmacol Toxicol. 1955;11:265–76.CrossRefGoogle Scholar
  561. 561.
    Elion GB. Allopurinol and other inhibitors of urate synthesis. Handb Exp Pharmacol. 1978;51:485–514.CrossRefGoogle Scholar
  562. 562.
    Farebrother DA, Hatfield P, Simmonds HA, et al. Experimental crystal nephropathy (one year study in the pig). Clin Nephrol. 1975;4:243–50.Google Scholar
  563. 563.
    Reiter S, Simmonds HA, Zollner N, et al. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin Chim Acta. 1990;187:221.PubMedCrossRefGoogle Scholar
  564. 564.
    Van Gennip AH, van Noordenburg Huistra D, de Bree PK, Wadman SK. Two-dimensional thin layer chromatography for the screening of disorders of purine and pyrimidine metabolism. Clin Chim Acta. 1978;96:7.CrossRefGoogle Scholar
  565. 565.
    Simmonds HA, Duley JA, Davies PM. Analyses of purines and pyrimidines in blood, urine, and other physiological fluids. In: Hommes F, editor. Techniques in diagnostic human biochemical genetics. A Laboratory Manual. New York: Wiley-Liss; 1991. p. 397.Google Scholar
  566. 566.
    Bennett MJ, Carpenter KH, Hill PG. Asymptomatic xanthinuria detected as a result of routine analysis of serum for urate. Clin Chem. 1985;31:492.PubMedGoogle Scholar
  567. 567.
    Boulieu R, Bory C, Baltassat P, Divry P. Hypoxanthine and xanthine concentrations determined by high performance liquid chromatography in biological fluids from patients with xanthinuria. Clin Chim Acta. 1984;142:83.PubMedCrossRefGoogle Scholar
  568. 568.
    Harkness RA, Coade SB, Walton KR, Wright D. Xanthine oxidase deficiency and “Dalmation” hypouricemia: Incidence and effect of exercise. J Inherit Metab Dis. 1983;6:114.PubMedCrossRefGoogle Scholar
  569. 569.
    Costello J, Al-Dabagh E. A new rapid spectrophotometric method for the detection of xanthinuria. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and related clinical research. New York: Plenum; 1985. p. 681.CrossRefGoogle Scholar
  570. 570.
    Holmes EW, Wyngaarden JB. Hereditary xanthinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill, Inc; 1989. p. 1090.Google Scholar
  571. 571.
    Simmonds HA, Levin B, Cameron JS. Variations in allopurinol metabolism by xanthinuric subjects. Clin Sci Mol Med. 1974;47:173.PubMedGoogle Scholar
  572. 572.
    Yamamoto T, Higashino K, Kono N, et al. Metabolism of pyrazinamide and allopurinol in hereditary xanthine oxidase deficiency. Clin Chim Acta. 1989;180:169.PubMedCrossRefGoogle Scholar
  573. 573.
    Auscher C, Pasquier C, Pehuet P, Delbarre F. Study of urinary pyrazinamide metabolites and their action on renal excretion of xanthine and hypoxanthine in a xanthinuric patient. Biomedicine. 1978;28:129.PubMedGoogle Scholar
  574. 574.
    Holmes EW, Mason DH, Goldstein LI, et al. Xanthine oxidase deficiency: studies of a previously unreported case. Clin Chem. 1974;20:1076.PubMedGoogle Scholar
  575. 575.
    Auscher C, Pasquier C, Amory N, et al. The effect of weight reduction on plasma and urinary levels of oxypurines in an obese xanthinuric patient. Adv Exp Med Biol. 1980;122A:241.PubMedCrossRefGoogle Scholar
  576. 576.
    Kojima T, Nishina T, Kitamura M, et al. Biochemical studies on the purine metabolism of four cases with hereditary xanthinuria. Clin Chim Acta. 1984;137:189.PubMedCrossRefGoogle Scholar
  577. 577.
    Hillebrand G, Reiter S. Hypourikamie – ein differentialdiagnostisches problem. Internist. 1991;32:226.PubMedGoogle Scholar
  578. 578.
    Reiter S, Simmonds HA, Zollner N, et al. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase forming oxipurinol. Clin Chim Acta. 1990;187:221.PubMedCrossRefGoogle Scholar
  579. 579.
    Laudaas S, Borch K, Aagaard E. A new case with hereditary xanthinuria: response to exercise. Clin Chim Acta. 1989;181:119.CrossRefGoogle Scholar
  580. 580.
    Engelman K, Watts RWE, Klinenberg JR, et al. Clinical, physiological and biochemical studies of a patient with xanthinuria and pheochromocytoma. Am J Med. 1964;37:839.PubMedCrossRefGoogle Scholar
  581. 581.
    Chalmers RA, Watts RWE, Pallis C, et al. Crystalline deposits in striped muscle in xanthinuria. Nature. 1969;221:170–1.PubMedCrossRefGoogle Scholar
  582. 582.
    Parker R, Snedden W, Watts RWE. The mass spectrophotometric identification of hypoxanthine and xanthine (“oxypurines”) in skeletal muscle from two patients with congenital xanthine oxidase deficiency (xanthinuria). Biochem J. 1969;115:103–8.Google Scholar
  583. 583.
    Crawhall JC, Itiaba K, Katz S. Separation and quantitation of oxypurines by isocratic high pressure liquid chromatography: application to xanthinuria and the Lesch-Nyhan syndrome. Biochem Med. 1983;30:261.PubMedCrossRefGoogle Scholar
  584. 584.
    Kawachi M, Kono N, Mineo I, et al. Decreased xanthine oxidase activities and increased urinary oxypurines in heterozygotes for hereditary xanthinuria. Clin Chim Acta. 1990;88:137.CrossRefGoogle Scholar
  585. 585.
    Castro-Liendoza HJ, Cifuentes-Delatte LC, Rapudo A. Una nueva observacion de xanthinuria familiar. Rev Clin Esp. 1972;124:341.Google Scholar
  586. 586.
    Kutter D, Humbel R, Bisdorff J. Biochemische untersuchungen bei einem typischen Fall von xanthinurie. Dtsch Med Wochenschr. 1970;95:1269.PubMedCrossRefGoogle Scholar
  587. 587.
    Simmonds HA, Reiter S, Nishino T. Hereditary xanthinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc.; 1995. p. 1789.Google Scholar
  588. 588.
    Ullmann H. Zur frage der harnsaureausscheidung in urin bei ikteruskranken. Klin Wochenschr. 1923;2:2174–5.CrossRefGoogle Scholar
  589. 589.
    Matz R, Christodoulou J, Vianna N, et al. Renal tubular dysfunction associated with alcoholism and liver disease. N Y State J Med. 1969;69:1312–4.PubMedGoogle Scholar
  590. 590.
    Passero G, Masini G. L’ipouricemia negli itteri colurici. Minerva Med. 1958;49:3155–8.Google Scholar
  591. 591.
    Van Peenen HJ. Causes of hyperuricemia. Ann Intern Med. 1973;78:977–8.PubMedGoogle Scholar
  592. 592.
    Casas E, Serrano C, Daimiel E, et al. Prevalence, physiopathology and processes associated with hypouricemia in a hospitalized population: analysis of 27,987 analytic determinations. Rev Clin Esp. 1990;186:211–5.PubMedGoogle Scholar
  593. 593.
    Diaz Curiel M, Zea Mendoza A, Rapado A, Gonzalez Villasante J. Significacion clinica de la hipouicemia en 14,685 determinaciones del autoanalizador. Rev Clin Esp. 1975;139:365.Google Scholar
  594. 594.
    Sperling O, Weinberger A, Pinkhas J, de Vries A. Frequency and causes of hypouricemia in hospital patients. Isr J Med Sci. 1977;13:529.PubMedGoogle Scholar
  595. 595.
    Hisatome I, Ogino K, Kotake H, et al. Cause of persistent hypouricemia in outpatients. Nephron. 1989;51:13.PubMedCrossRefGoogle Scholar
  596. 596.
    Yanasze M, Nakahama H, Mikami H, et al. Prevalence of hypouricemia in apparently normal population. Nephron. 1988;48:80.CrossRefGoogle Scholar
  597. 597.
    Simmonds HA, Van Acker KJ. Adenine phosphoribosyltransferase deficiency: 2,8-dihydroxyadenine lithiasis. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill, Inc; 1983. p. 1144–56.Google Scholar
  598. 598.
    Coupris L, Champion G, Duverne C, et al. 2,8-dihydroxyadenine lithiasis. Two new pediatric cases of this misdiagnosed metabolic abnormality. The value of extracorporeal lithotripsy. Chir Pediatr. 1989;30:253.PubMedGoogle Scholar
  599. 599.
    Yagisawa T, Yamazaki Y, Toma H, Kamatani N. Radiopaque 2,8-dihydroxyadenine lithiasis. Int Urol Nephrol. 1999;31:141.PubMedCrossRefGoogle Scholar
  600. 600.
    Simmonds HA, Sahota AS, Van Acker KJ. Adenine phosphoribosyltransferase deficiency and 2,8-dihydroxyadenine lithiasis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc; 1995. p. 1704.Google Scholar
  601. 601.
    Ceballos-Picot I, Perignon JL, Hamet M, et al. 2,8-dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet. 1992;339:1050.PubMedCrossRefGoogle Scholar
  602. 602.
    Takemoto M, Nagano S. Urolithiasis containing 2,8-dihydroxyadenine: report of a case. Acta Urol (Jpn). 1979;25:265.Google Scholar
  603. 603.
    Gliklich D, Gruber HE, Matas AJ, et al. 2,8-dihydroxyadenine lithiasis. Report of a case first diagnosed after renal transplant. Q J Med. 1988;69:785.Google Scholar
  604. 604.
    Greenwood MC, Dillon MJ, Simmonds HA, et al. Renal failure due to 2,8-dihydroxyadenine urolithiasis. Eur J Pediatr. 1982;138:346.PubMedCrossRefGoogle Scholar
  605. 605.
    Schabel F, Doppler W, Hirsch-Kauffmann M, et al. Hereditary deficiency of adenine phosphoribosyltransferase. Paediatr Paedol. 1980;15:233.Google Scholar
  606. 606.
    Joost J, Doppler W. The 2,8-dihydroxyadenine stone in childhood. Urology. 1982;20:67.PubMedCrossRefGoogle Scholar
  607. 607.
    Laxdal T, Jonasson TA. Adenine phosphoribosyltransferase deficiency in Iceland. Acta Med Scand. 1988;224:621.PubMedCrossRefGoogle Scholar
  608. 608.
    Gleeson MJ, Griffith DP. Distribution of patients with 2,8-dihydroxyadenine urolithiasis and adenine phosphoribosyltransferase deficiency in Japan. J Urol. 1989;142:834.PubMedGoogle Scholar
  609. 609.
    Cartier P, Hamet M. Une nouvelle maladie metabolique: le deficit complet en adenine-phosphoribosyltransferase avec lithiasise de 2,8-dihydroxyadenine. C R Acad Sci (Paris). 1974;279:883.Google Scholar
  610. 610.
    Simmonds HA, Van Acker KJ, Cameron JS, Snedden W. The identification of 2,8-dihydroxyadenine, a new component of urinary stones. Biochem J. 1986;157:485.Google Scholar
  611. 611.
    Simmonds HA, Potter CF, Sahota A, et al. Adenine phosphoribosyltransferase deficiency presenting with supposed uric acid stones; pitfalls of diagnosis. J R Soc Med. 1978;71:791.PubMedGoogle Scholar
  612. 612.
    Simmonds HA. 2,8-dihydroxyadeninuria, or when is a uric acid stone not a uric acid stone? Clin Nephrol. 1979;12:195.PubMedGoogle Scholar
  613. 613.
    Reveillaud RJ, Daudon M, Protat MF, et al. Lithiase 2,8-dihydroxyadenique: un nouveau cas depiste par analyse infra-rouge. Nouv Presse Med. 1979;8:2965.PubMedGoogle Scholar
  614. 614.
    Johnson LA, Gordon RB, Emmerson BT. Adenine phosphoribosyltransferase: a simple spectrophotometric assay and the incidence of mutation in the normal population. Biochem Genet. 1977;15:256.Google Scholar
  615. 615.
    Fox IH, LaCroix S, Planet G, Moore M. Partial deficiency of adenine phosphoribosyltransferase in man. Medicine. 1977;56:515.PubMedCrossRefGoogle Scholar
  616. 616.
    Emmerson BT, Gordon RB, Thompson L. Adenine phosphoribosyltransferase deficiency: its inheritance and occurrence in a female with gout and renal disease. Aust N Z J Med. 1975;5:440.PubMedCrossRefGoogle Scholar
  617. 617.
    Kelley WN, Levy RI, Rosenbloom FM, et al. Adenine phosphoribosyltransferase deficiency – a previously undescribed genetic defect in man. J Clin Invest. 1968;47:2281.PubMedCrossRefGoogle Scholar
  618. 618.
    Fox IH, Meade JC, Kelley WN. Adenine phosphoribosyltransferase deficiency in man. Am J Med. 1973;55:614.PubMedCrossRefGoogle Scholar
  619. 619.
    Delbarre F, Auscher C, Amor B, et al. Gout with adenine phosphoribosyltransferase deficiency. Biomedicine. 1974;21:82.PubMedGoogle Scholar
  620. 620.
    Kojima T, Nishina T, Kamatani N, Nishioka K. Reversed-phase high-performance liquid chromatography of 2,8-dihydroxyadenine in serum and urine with electrochemical detection. Clin Chim Acta. 1989;181:109.PubMedCrossRefGoogle Scholar
  621. 621.
    Doppler W, Hirsch-Kauffmann M, Schabel F, Schweiger M. Characterization of the biochemical basis of a complete deficiency of the adenine phosphoribosyltransferase (APRT). Hum Genet. 1984;57:404.CrossRefGoogle Scholar
  622. 622.
    Feigleson P, Davidson JD, Robins RK. Pyrazolopy­rimidines as inhibitors and substrates of xanthine oxidase. J Biol Chem. 1957;226:993–1000.Google Scholar
  623. 623.
    Krenitsky TA, Elion GB, Strelitz RA, Hitchings GH. Ribonucleosides of allopurinol and oxoallopurinol. J Biol Chem. 1967;242:2675–82.PubMedGoogle Scholar
  624. 624.
    Langrebe AR, Nyhan WL, Coleman M. Urinary tract stones resulting from the excretion of oxipurinol. N Engl J Med. 1975;292:626–7.CrossRefGoogle Scholar
  625. 625.
    Stote RM, Smith LH, Dubb JW, et al. Oxipurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med. 1980;92:384–5.PubMedGoogle Scholar
  626. 626.
    Prien EL, Prien Jr EL. Composition and structure of urinary stone. Am J Med. 1968;45:654–72.PubMedCrossRefGoogle Scholar
  627. 627.
    Talbott JH. Gout. New York: Grune & Stratton; 1957. p. 205.Google Scholar
  628. 628.
    Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med. 1977;87:404–10.PubMedGoogle Scholar
  629. 629.
    Coe FL, Moran E, Kavalach AG. The contribution of dietary protein over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis. 1976;29:793–800.PubMedCrossRefGoogle Scholar
  630. 630.
    Coe FL. Association of calcium nephrolithiasis with disorders of uric acid metabolism. Handb Exp Pathol. 1978;51:423.CrossRefGoogle Scholar
  631. 631.
    Coe FL, Raisen L. Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet. 1973;1:129–31.PubMedCrossRefGoogle Scholar
  632. 632.
    Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med. 1974;291:1344–50.PubMedCrossRefGoogle Scholar
  633. 633.
    Smith MJV. Placebo versus allopurinol for renal calculi. J Urol. 1977;117:690–2.PubMedGoogle Scholar
  634. 634.
    Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315:1386–9.PubMedCrossRefGoogle Scholar
  635. 635.
    Pak CYC, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med. 1986;146:863–7.PubMedCrossRefGoogle Scholar
  636. 636.
    Pak CYC, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986;30:422–8.PubMedCrossRefGoogle Scholar
  637. 637.
    Noda S, Hayashi K, Eto K. Oxalate crystallization in the kidney in the presence of hyperuricemia. Scanning Microsc. 1989;3:829.PubMedGoogle Scholar
  638. 638.
    Gover PK, Ryall RL, Marshall VR. Dissolved urate promotes calcium oxalate crystallization: epitaxy is not the cause. Clin Sci (Colch). 1993;85:303.Google Scholar
  639. 639.
    Suki WN, Hull AR, Rector Jr FC, et al. Mechanism of the effect of thiazide diuretics on calcium and uric acid. J Clin Invest. 1967;46:1121.Google Scholar
  640. 640.
    Wyngaarden JB. Diuretics and hyperuricemia. N Engl J Med. 1970;283:1170.CrossRefGoogle Scholar
  641. 641.
    Cannon PJ, Heinemann H, Stason WB, et al. Ethacrynic acid. Effectiveness and mode of diuretic action in man. Circulation. 1965;31:5.PubMedCrossRefGoogle Scholar
  642. 642.
    Steele TH. Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. J Lab Clin Med. 1969;74:288.PubMedGoogle Scholar
  643. 643.
    Schirmeister J, Man NK, Hallauer W. Lactate and uric acid following oral diuretic drug administration in man. Klin Wochenschr. 1967;45:1219.PubMedCrossRefGoogle Scholar
  644. 644.
    Schirmeister J, Man NK, Warning D, Hallauer W. On the question of an extrarenal cause for uric acid retention after furosemide. Verh Dtsch Ges Inn Med. 1967;73:1025.PubMedGoogle Scholar
  645. 645.
    Park YB, Park YS, Song J, et al. Clinical manifestations of Korean female gouty patients. Clin Rheumatol. 2000;19:142.PubMedCrossRefGoogle Scholar
  646. 646.
    Hayem G, Delahousse M, Meyer O, et al. Female premenopausal tophaceous gout induced by long-term diuretic abuse. J Rheumatol. 1996;23:2166.PubMedGoogle Scholar
  647. 647.
    Puig JG, Mechan AD, Jiminez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151:726.PubMedCrossRefGoogle Scholar
  648. 648.
    Meyers OL, Monteagudo FS. A comparison of gout in men and women. A 10-year experience. S Afr Med J. 1986;70:721.PubMedGoogle Scholar
  649. 649.
    Lally EV, Ho Jr G, Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med. 1986;146:2221.PubMedCrossRefGoogle Scholar
  650. 650.
    Meyers OL, Monteagudo FS. Gout in females: an analysis of 92 patients. Clin Exp Rheumatol. 1985;3:105.PubMedGoogle Scholar
  651. 651.
    Scott JT, Higgins CS. Diuretic induced gout: a multifactorial condition. Ann Rheum Dis. 1992;51:259.PubMedCrossRefGoogle Scholar
  652. 652.
    Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501.PubMedGoogle Scholar
  653. 653.
    Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045.PubMedGoogle Scholar
  654. 654.
    Nicotero JA, Scheib ET, Martinez R, et al. Prevention of hyperuricemia by allopurinol in hypertensive patients treated with chlorothiazide. N Engl J Med. 1970;282:133.PubMedCrossRefGoogle Scholar
  655. 655.
    Brest AN, Heider C, Mehbod H, et al. Drug control of diuretic-induced hyperuricemia. JAMA. 1966;195:132.CrossRefGoogle Scholar
  656. 656.
    Emmerson BT. A comparison of uricosuric agents in gout with special reference to sulfinpyrazone. Med J Aust. 1963;1:839.Google Scholar
  657. 657.
    Yu TF, Gutman AB. Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med. 1955;90:542.PubMedGoogle Scholar
  658. 658.
    Gutman AB, Yu TF. Effect of salicylate in varying dosage on urinary urate excretion in gouty subjects. Ann Rheum Dis. 1955;14:444.CrossRefGoogle Scholar
  659. 659.
    Grayzel AI, Liddle L, Seegmiller JE. Diagnostic significance of hyperuricemia in arthritis. N Engl J Med. 1961;265:763.PubMedCrossRefGoogle Scholar
  660. 660.
    See G. Etudes sur l’acid salicylique et lest salicylates: traitment du rheumatisme aigu et chronique, de la goutte, et de diverses affections du systeme nerveux sensitif par les salicylates. Bull Acad Med Paris. 1877;6:689, 717, 926, 937, 1024.Google Scholar
  661. 661.
    Yu TF, Dayton PG, Gutman AB. Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: a study in interactions between drugs. J Clin Invest. 1963;42:1330.CrossRefGoogle Scholar
  662. 662.
    Lieber CS, Davidson CS. Some metabolic effects of ethyl alcohol. Am J Med. 1962;33:319.PubMedCrossRefGoogle Scholar
  663. 663.
    Lieber CS, Jones DP, Losowsky MS, et al. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest. 1962;41:1863.PubMedCrossRefGoogle Scholar
  664. 664.
    MacLachlan MJ, Rodnan JP. Effects of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med. 1967;42:38.PubMedCrossRefGoogle Scholar
  665. 665.
    Newcombe DS. Ethanol metabolism and uric acid. Metabolism. 1972;21:1193.PubMedCrossRefGoogle Scholar
  666. 666.
    Olin JA, Devenyi P, Weldon KL. Uric acid in alcoholics. Q J Stud Alcohol. 1973;34:1202.PubMedGoogle Scholar
  667. 667.
    Cullen JH, Early LJA, Fiore JM. The occurrence of hyperuricemia during pyrazinamide-isoniazide therapy. Am Rev Tuberc. 1956;74:289.PubMedGoogle Scholar
  668. 668.
    Inoue T, Iheda N, Kurasawa T, et al. Hyperuricemia and arthralgias during pyrazinamide treatment. Nihon Kokyuki Gakkai Zasshi. 1999;37:115.PubMedCrossRefGoogle Scholar
  669. 669.
    Koumbaniou C, Nicopoulaaaos G, Vassilion M, et al. Is pyrazinamide really the third drug of choice in the treatment of tuberculosis. Int J Tuberc Lung Dis. 1998;2:675.PubMedGoogle Scholar
  670. 670.
    Steele TH, Rieselbach RE. The renal mechanism for urate homeostasis in normal man. Am J Med. 1967;43:868.PubMedCrossRefGoogle Scholar
  671. 671.
    Gutman AB, Yu TF, Berger L. Renal function in gout. III. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid). Am J Med. 1969;47:575.PubMedCrossRefGoogle Scholar
  672. 672.
    Weiner IM, Tinker JP. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J Pharmacol Exp Ther. 1972;180:411.PubMedGoogle Scholar
  673. 673.
    Shapiro M, Hyde L. Hyperuricemia due to pyrazinamide. Am J Med. 1957;23:596.PubMedCrossRefGoogle Scholar
  674. 674.
    Kanner O, Jacobs P. Elevation of blood serum uric acid levels with chemotherapy. Transactions. 1957;16:244.Google Scholar
  675. 675.
    Wood RHN. Salicylates. Bull Rheum Dis. 1963;13:297.PubMedGoogle Scholar
  676. 676.
    Petty TL, Dalrymple GV. Inhibition of pyrazinamide hyperuricemia by small doses of acetylsalicylic acid. Ann Intern Med. 1964;60:898.PubMedGoogle Scholar
  677. 677.
    Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia due to ethambutol. N Engl J Med. 1972;286:761.PubMedCrossRefGoogle Scholar
  678. 678.
    Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia induced by ethambutol. Adv Exp Med Biol. 1974;41B:763.Google Scholar
  679. 679.
    Palestine AG, Nussenblat RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing tranplantation. Am J Med. 1984;77:652.PubMedCrossRefGoogle Scholar
  680. 680.
    Tiller DJ, Hall BM, Hovrath JS, et al. Gout and hyperuricemia in patients on cyclosporine and diuretics. Lancet. 1985;1:453.PubMedCrossRefGoogle Scholar
  681. 681.
    Chapman JR, Griffiths D, Harding NG, Morris PJ. Reversibility of cyclosporine nephrotoxicity after three month’s treatment. Lancet. 1985;1:128.PubMedCrossRefGoogle Scholar
  682. 682.
    VanHooff JP, Leunissen KML, vande Staak W. Cyclosporin, uric acid, and the kidney. Lancet. 1985;1:201.Google Scholar
  683. 683.
    Najarian JS, Fryd DS, Strand M, et al. A single institution randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allografts recipients. Ann Surg. 1985;201:142.PubMedCrossRefGoogle Scholar
  684. 684.
    Burack DA, Griffith BP, Thompson ME, Kohl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92:141.PubMedCrossRefGoogle Scholar
  685. 685.
    Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974.PubMedGoogle Scholar
  686. 686.
    Pela I, Seracini D, Lavoratti G, Materassi M. Acute gouty arthritis in adolescents with renal transplants. Pediatr Med Chir. 1999;21:135.PubMedGoogle Scholar
  687. 687.
    Johnson DW, Saunders HJ, Johnson FJ, et al. Fibrogenic effects of cyclosporin A on the tubulointerstitium: role of cytokines and growth factors. Exp Nephrol. 1999;7:470.PubMedCrossRefGoogle Scholar
  688. 688.
    Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without cyclosporin A. Nephron. 1998;80:450.PubMedCrossRefGoogle Scholar
  689. 689.
    Edvardsson VO, Kaiser BA, Polinsky MS, et al. Natural history and etiology of hyperuricemia following pediatric renal transplantation. Pediatr Nephrol. 1995;9:57.PubMedCrossRefGoogle Scholar
  690. 690.
    Laine J, Holmberg C. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron. 1996;74:318.PubMedCrossRefGoogle Scholar
  691. 691.
    Zurcher RM, Bock HA, Thiel G. Hyperuricaemia in cyclosporine-treated patients: GFR-related effect. Nephrol Dial Transplant. 1996;11:153.PubMedCrossRefGoogle Scholar
  692. 692.
    Peeters P, Sennesael J. Low back pain caused by spinal tophus: a complication of gout in a kidney transplant recipient. Nephrol Dial Transplant. 1998;13:3245.PubMedCrossRefGoogle Scholar
  693. 693.
    Hausch R, Wilkerson M, Singh E, et al. Tophaceous gout of the thoracic spine presenting as back pain and fever. J Clin Rheumatol. 1999;6:335.CrossRefGoogle Scholar
  694. 694.
    Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy. 1987;7:165.PubMedGoogle Scholar
  695. 695.
    Cummins D, Sekar M, Halil M, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996;61:1661.PubMedCrossRefGoogle Scholar
  696. 696.
    Byrne PAC, Fraser AG, Pritchard MH. Treatment of gout following cardiac transplantation. Br J Rheumatol. 1996;35:1329.PubMedGoogle Scholar
  697. 697.
    Jacobs F, Mamzer-Bruneel MF, Skhiri H, et al. Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. Transplantation. 1997;64:2087.CrossRefGoogle Scholar
  698. 698.
    Perez Ruiz F, Calaboro M, Ferenendez Lopez J, et al. Treatment of chronic gout in patients with renal function impairment. J Clin Rheumatol. 1999;5:49.PubMedCrossRefGoogle Scholar
  699. 699.
    Flury W, Ruch HR, Montandon A. The treatment of hyperuricemia after kidney transplantation. Schweiz Med Wochenschr. 1977;107:1339.PubMedGoogle Scholar
  700. 700.
    Imanishi M, Ikegami M, Ishii T, et al. Clinical studies on hyperuricemia and gout after transplantation. Hinyokika Kiyo. 1990;36:893.PubMedGoogle Scholar
  701. 701.
    Matzkies F. Effects and side effects of Benzbromarone in the initial treatment of hyperuricemia and gout. Results of a field study of 3899 patients. Fortschr Med. 1978;96:1619.PubMedGoogle Scholar
  702. 702.
    Gehenot M, Horsmans V, Rahier J, Geubel AP. Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol. 1994;20:842.PubMedCrossRefGoogle Scholar
  703. 703.
    Diamond HS. Uricosuric drugs. Handb Exp Pharmacol. 1977;51:459.CrossRefGoogle Scholar
  704. 704.
    Sinclair DS, Fox IH. The pharmacology of the hypouricemic effect of Benzbromarone. J Rheumatol. 1975;2:437.PubMedGoogle Scholar
  705. 705.
    Camus JP, Prier A, Kartun P, et al. Thyreotoxicose et benziodarone. Rev Rhum. 1973;40:2, 148.Google Scholar
  706. 706.
    Davis S, Park YK, Abuchowski A, Davis FF. Hypouricemic effect of polyethylene glycol modified urate oxidase. Lancet. 1987;2:281.Google Scholar
  707. 707.
    Chua CC, Greenberg LL, Viau AT, et al. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1988;109:114.PubMedGoogle Scholar
  708. 708.
    Ippoliti G, Negri M, Campana C, Vigano M. Urate oxidase in hyperuricemic heart transplant recipients treated with azathioprine. Transplantation. 1997;63:1370.PubMedCrossRefGoogle Scholar
  709. 709.
    Rozenberg S, Koeger AC, Bourgeois P. Urate-oxidase for gouty arthritis in cardiac transplant recipients. J Rheumatol. 1973;20:2171.Google Scholar
  710. 710.
    Rozenberg S, Roche B, Dorent R, et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. Rev Rhum Engl Ed. 1995;65:392.Google Scholar
  711. 711.
    Royer R, Lamarche M, Kissel P. Etude de l’action d’une urate-oxydase fongique sur l’uricemie et l’excretion de l’azote urique chez l’homme. Therapie. 1967;22:1113.PubMedGoogle Scholar
  712. 712.
    Brogard JM, Coumaros D, Frankhauser J, et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Eur J Clin Biol Res. 1972;17:890.Google Scholar
  713. 713.
    Mourad G, Cristol JP, Chong G, et al. Role of precipitating anti-urate oxidase antibodies in urate oxidase-resistant hyperuricemia. Presse Med. 1984;13:2585.PubMedGoogle Scholar
  714. 714.
    Wolf G, Hegewisch-Becher S, Hossfeld DK, Stahl RA. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis. 1999;34:E20.PubMedCrossRefGoogle Scholar
  715. 715.
    Pui CH, Relling MV, Lascombe F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813.PubMedCrossRefGoogle Scholar
  716. 716.
    Seidemann K, Meyer U, Jansen P, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin’s lymphoma and B-ALL. Observations from the BFM trials. Klin Padiatr. 1998;210:279.PubMedCrossRefGoogle Scholar
  717. 717.
    Rana SS, Guiliani MJ, Oddis ChV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg. 1997;99:266.PubMedCrossRefGoogle Scholar
  718. 718.
    Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264.PubMedGoogle Scholar
  719. 719.
    Garg G, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723.PubMedCrossRefGoogle Scholar
  720. 720.
    Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol. 1998;82:67u, 85u.PubMedCrossRefGoogle Scholar
  721. 721.
    Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med. 1974;84:179.PubMedGoogle Scholar
  722. 722.
    Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med. 1993;153:2050.PubMedCrossRefGoogle Scholar
  723. 723.
    Christensen A, Achor WP, Berge KG, et al. Nicotinic acid treatment of hypercholesterolemia. JAMA. 1961;177:546.PubMedCrossRefGoogle Scholar
  724. 724.
    Parsons WB. Studies of nicotinic acid use in hypercholesterolemia. Arch Intern Med. 1961;107:653.PubMedCrossRefGoogle Scholar
  725. 725.
    Berge KG, Achor WP, Christensen NA, et al. Hypercholesterolemia and nicotinic acid: a long term study. Am J Med. 1961;31:25.CrossRefGoogle Scholar
  726. 726.
    Gant ZN, Pocelinko R, Solomon AM, et al. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism. 1971;20:1031.CrossRefGoogle Scholar
  727. 727.
    Becker MA, Raivio KO, Meyer LJ, et al. Effects of nicotinic acid on human purine metabolism. Clin Res. 1973;21:616.Google Scholar
  728. 728.
    Shuster L, Abraham G. The effect of nicotinamide on incorporation in vivo of formate-C14. J Biol Chem. 1959;234:129.PubMedGoogle Scholar
  729. 729.
    Shuster L, Goldin A. The incorporation of C14 glucose and C14 ribose into mouse diphosphopyridine nucleotide. J Biol Chem. 1958;230:873.PubMedGoogle Scholar
  730. 730.
    Boyle JA, Raivio KO, Becker MA, et al. Effects of nicotinic acid on human fibroblast purine biosynthesis. Biochim Biophys Acta. 1972;269:179.PubMedCrossRefGoogle Scholar
  731. 731.
    Oberhaemsli RD, Rajagopalan B, Taylor DJ. Study of hereditary fructose intolerance by use of 31-P magnetic resonance spectroscopy. Lancet. 1987;2:931.CrossRefGoogle Scholar
  732. 732.
    Seegmiller JE, Dixon RM, Kemp GJ, et al. Fructose-induced aberration of metabolism in familial gout identified by 31-P magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1990;87:8326.PubMedCrossRefGoogle Scholar
  733. 733.
    Steinmann B, Gitzelmann R. The diagnosis of hereditary fructose intolerance. Helv Paediatr Acta. 1981;36:297.PubMedGoogle Scholar
  734. 734.
    Perheentupa J, Raivio K. Fructose-induced hyperuricemia. Lancet. 1967;2:528.PubMedCrossRefGoogle Scholar
  735. 735.
    Fox IH, Kelley WN. Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism. 1972;21:713.PubMedCrossRefGoogle Scholar
  736. 736.
    Narins RG, Weisberg JS, Myers AR. Effects of carbohydrates on uric acid metabolism. Metabolism. 1974;23:455.PubMedCrossRefGoogle Scholar
  737. 737.
    Peaston MJT. Dangers of intravenous fructose. Lancet. 1973;1:266.PubMedCrossRefGoogle Scholar
  738. 738.
    Kogut MD, Roe TF, Ng W, Nonnel GN. Fructose-induced hyperuricemia: observations in normal ­children and in patients with hereditary fructose intolerance and galactosemia. Pediatr Res. 1975;9:774.PubMedCrossRefGoogle Scholar
  739. 739.
    Sahebjami DH, Scalettar R. Effect of fructose infusion on lactate and uric acid metabolism. Lancet. 1971;1:366.PubMedCrossRefGoogle Scholar
  740. 740.
    Edwards NL, Gelfand EW, Biggar D, Fox IH. Partial deficiency of purine nucleoside phosphorylase: studies of purine and pyrimidine metabolism. J Lab Clin Med. 1978;91:736.PubMedGoogle Scholar
  741. 741.
    Kurtz TW, Kabra PM, Booth BE, et al. Liquid chromatographic measurements of inosine, hypoxanthine and xanthine in studies of fructose-induced degradation of adenine nucleotides in humans and rats. Clin Chem. 1986;32:782.PubMedGoogle Scholar
  742. 742.
    Bode JC, Zelder O, Rumpelt HJ, Wittkamp U. Depletion of liver adenosine phosphates and metabolic effects of intravenous infusion of fructose and sorbitol in man and in the rat. Eur J Clin Invest. 1973;3:436.PubMedCrossRefGoogle Scholar
  743. 743.
    Hultman E, Nilsson LH, Sahlin K. Adenine nucleotide content of human liver. Normal values and fructose-induced depletion. Scand J Clin Lab Invest. 1975;35:245.PubMedCrossRefGoogle Scholar
  744. 744.
    Buchli R, Meier D, Martin E, Boesiger P. Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part II. Muscle, liver, kidney. Magn Reson Med. 1994;32:453.PubMedCrossRefGoogle Scholar
  745. 745.
    Boesiger P, Buchli R, Meier D, et al. Changes of liver metabolite concentrations in adults with disorders of fructose metabolism after intravenous fructose by 31P magnetic resonance spectroscopy. Pediatr Res. 1994;36:436.PubMedCrossRefGoogle Scholar
  746. 746.
    Oberhaensli RD, Galloway GJ, Taylor DJ, et al. Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol. 1986;59:695.PubMedCrossRefGoogle Scholar
  747. 747.
    Dufour JF, Stoupis C, Lazeyras F, et al. Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic 31phosphorus spectroscopy. Hepatology. 1992;15:835.PubMedCrossRefGoogle Scholar
  748. 748.
    Sukuma H, Itabashi K, Takeda K, et al. Serial P-31 MR spectroscopy after fructose infusion in patients with chronic hepatitis. J Magn Reson Imaging. 1991;1:701.CrossRefGoogle Scholar
  749. 749.
    Van den Berghe G, Bronfman M, Vanneste R, Hers HG. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. Biochem J. 1977;162:601.PubMedGoogle Scholar
  750. 750.
    Lamers JMJ, Hulsmann WC. The effect of fructose on the stores of energy-rich phosphate in rat jejunum in vivo. Biochim Biophys Acta. 1973;313:1.PubMedCrossRefGoogle Scholar
  751. 751.
    Burch HB, Lowry OH, Meinhardt L, et al. Effect of fructose, dihydroxyacetone, glycerol, and glucose on metabolites and related compounds in liver and kidney. J Biol Chem. 1970;245:2092.PubMedGoogle Scholar
  752. 752.
    Morris RC, Nigon K, Reed EB. Evidence that the depletion of inorganic phosphate determines the severity of the disturbance of adenine nucleotide metabolism in the liver and renal cortex of the fructose-loaded rat. J Clin Invest. 1978;61:209.PubMedCrossRefGoogle Scholar
  753. 753.
    Raivio KO, Becker MA, Meyer LJ, et al. Stimulation of human purine synthesis de novo by fructose infusion. Metabolism. 1975;24:861.PubMedCrossRefGoogle Scholar
  754. 754.
    Itakura M, Sabina RL, Heald PW, Holmes EW. Basis for the control of purine biosynthesis by purine ribonucleotides. J Clin Invest. 1981;67:994.PubMedCrossRefGoogle Scholar
  755. 755.
    Vincent MF, Van den Berghe G, Hers HG. Increase in phosphoribosyl pyrophosphate induced by ATP and Pi depletion in hepatocytes. FASEB J. 1989;3:1862.PubMedGoogle Scholar
  756. 756.
    Kaye R, Williams ML, Barbero G. Comparative study of glucose and fructose metabolism in infants with reference to utilization and to the accumulation of glycolytic intermediates. J Clin Invest. 1958;37:752.PubMedCrossRefGoogle Scholar
  757. 757.
    Riddle MC. Endogenous uric acid metabolism in pernicious anemia. J Clin Invest. 1929;8:69.PubMedCrossRefGoogle Scholar
  758. 758.
    Opsahl R. Hematopoiesis and endogenous uric acid. Acta Med Scand. 1939;102:611.CrossRefGoogle Scholar
  759. 759.
    Krafka Jr J. Endogenous uric acid and hematopoiesis. II. Uric acid, reticulocytosis and erythrocytes after hemolysis by phenylhydrazine hydrochloride. J Biol Chem. 1929;83:409.Google Scholar
  760. 760.
    Sears WG. The occurrence of gout during treatment of pernicious anemia. Lancet. 1933;1:24.CrossRefGoogle Scholar
  761. 761.
    Fox IH, Dotten DA, Marchant PJ. Alterations of human purine metabolism in megaloblastic anemia. Adv Exp Med Biol. 1977;76B:249.PubMedCrossRefGoogle Scholar
  762. 762.
    Luhby AL, Cooperman JM. Aminoimidazole­carboxamide excretion in vitamin-B12 and folic acid deficiencies. Lancet. 1962;2:1381.PubMedCrossRefGoogle Scholar
  763. 763.
    Newcombe DS. The urinary excretion of aminoimidazolecarboxamide in the Lesch-Nyhan syndrome. Pediatrics. 1970;46:508.PubMedGoogle Scholar
  764. 764.
    Hernandez Nieto L, Brito Barroso ML, Nyhan WL. Anemia megaloblastica en la enfremedad de Lesch-Nyhan. Sangre (Barc). 1984;29:476.Google Scholar
  765. 765.
    Manzke H. Hyperuricamie mit cerebralparese syndrom eines hereditaren purinstoffwechselleidens. Helv Paediatr Acta. 1967;22:258.PubMedGoogle Scholar
  766. 766.
    Marie J, Royer P, Rappaport R. Hyperuricemie congenitale avec troubles neurologiques, renaux et sanguins. Arch Fr Pediatr. 1967;24:401.Google Scholar
  767. 767.
    van der Zee SPM, Monnens LAH, Schretlen EDAM. Een hereditaire purinestoffwisselsstoormis met een cerebrale aandoening en megaloblastaire anemie (syndroom von Lesch en Nyhan). Ned Tijdschr Geneeskd. 1968;112:1475.PubMedGoogle Scholar
  768. 768.
    van der Zee SPM, Lommen EJP, Trijbels JMF, Schretlen EDAM. The influence of adenine on the clinical feature and purine metabolism in the ­Lesch-Nyhan syndrome. Acta Paediatr Scand. 1970;59:259.PubMedCrossRefGoogle Scholar
  769. 769.
    Henderson DA. The aetiology of chronic nephritis in Queensland. Med J Aust. 1958;1:377.Google Scholar
  770. 770.
    Ball GV, Sorensen LB. Pathogenesis of hyperuricemia in saturnine gout. N Engl J Med. 1968; 280:1199.CrossRefGoogle Scholar
  771. 771.
    Schwartz J, Levin R. The risk of lead toxicity in homes with lead paint hazard. Environ Res. 1991; 54:1.PubMedCrossRefGoogle Scholar
  772. 772.
    Delcourt JL, Hamrick HJ, O’Tauma LA, et al. Increased lead burden in children of battery workers: asymptomatic exposure resulting from contaminated work clothing. Pediatrics. 1978;62:563.Google Scholar
  773. 773.
    Garrettson LK. Childhood lead poisoning in radiator mechanics’ children. Vet Hum Toxicol. 1988;30:112.PubMedGoogle Scholar
  774. 774.
    Kaye WE, Novotny TE, Tucker M. New ceramics-related industry implicated in elevated blood lead levels in children. Arch Environ Health. 1987;42: 161.PubMedCrossRefGoogle Scholar
  775. 775.
    Committee on Lead in the Human Environment: Environmental studies board, Commission on Natural Resources, National Research Council, National Academy of Sciences; 1980.Google Scholar
  776. 776.
    Crutcher JE. Clinical manifestations and therapy of acute lead intoxication due to the ingestion of illicitly distilled alcohol. Ann Intern Med. 1963;59:707.PubMedGoogle Scholar
  777. 777.
    CDC. Elevated blood lead levels associated with illicitly distilled alcohol – Alabama, 1990–1991. MMWR Morb Mortal Wkly Rep. 1992;41:294.Google Scholar
  778. 778.
    Mustajoki P. Lead poisoning from illicit alcohol. Duodecim. 1978;94:993.PubMedGoogle Scholar
  779. 779.
    Ellis T, Lacy R. Illicit alcohol (moonshine) consumption in West Alabama revisited. South Med J. 1998;91:858.PubMedCrossRefGoogle Scholar
  780. 780.
    Lacy R, Winternitz WW. Moonshine consumption in West Alabama. Ala J Med Sci. 1984;21:364.PubMedGoogle Scholar
  781. 781.
    Pegues DA, Hughes BJ, Woernle CH. Elevated blood lead levels associated with illegally distilled alcohol. Arch Intern Med. 1993;153:1501.PubMedCrossRefGoogle Scholar
  782. 782.
    Halla JT, Ball GV. Saturnine gout: a review of 42 patients. Semin Arthritis Rheum. 1982;11:307.PubMedCrossRefGoogle Scholar
  783. 783.
    Montgomery R, Finkenbine R. A brief review of moonshine use. Psychiatr Serv. 1999;50:1088.PubMedGoogle Scholar
  784. 784.
    Ball GV. Two epidemics of gout. Bull Hist Med. 1971;45:401.PubMedGoogle Scholar
  785. 785.
    Baker G. An essay concerning the cause of the endemial colic of Devonshire. London: J. Hughs; 1767.Google Scholar
  786. 786.
    Sherlock JC, Pickford CJ, White GF. Lead in alcoholic beverages. Food Addit Contam. 1986;3:347.PubMedCrossRefGoogle Scholar
  787. 787.
    Molinini R, Caravella R, Carino M, Nuzzaco A. Three cases of poisoning caused by wine contaminated with lead. G Ital Med Lav. 1985;7:101.PubMedGoogle Scholar
  788. 788.
    Hight SC. Lead migration from lead crystal wine glasses. Food Addit Contam. 1996;13:747.PubMedCrossRefGoogle Scholar
  789. 789.
    Probst-Hensch N, Braun-Fabrlaender C, Bodenmann A, Ackermann-Liebrich U. Alcohol consumption and other lifestyle factors: avoidable sources of excess lead exposure. Soz Praventivmed. 1993;38:43.PubMedCrossRefGoogle Scholar
  790. 790.
    Tumpowsky CM, Davis LK, Rabin R. Elevated blood lead levels among adults in Massachusetts, 1991–1995. Public Health Rep. 2000;115:364.PubMedCrossRefGoogle Scholar
  791. 791.
    Garrod AB. The nature and treatment of gout and rheumatic gout. London: Walton & Maberg; 1859.Google Scholar
  792. 792.
    Emmerson BT. Chronic lead nephropathy. Kidney Int. 1973;4:1.PubMedCrossRefGoogle Scholar
  793. 793.
    Emmerson BT. Chronic lead nephropathy: the diagnostic uses of calcium EDTA and the association with gout. Australas Ann Med. 1963;12:310.PubMedGoogle Scholar
  794. 794.
    Emmerson BT. The clinical differentiation of lead gout from primary gout. Arthritis Rheum. 1968; 11:623.PubMedCrossRefGoogle Scholar
  795. 795.
    Reynolds PR, Knapp MJ, Baraf HSB, Holmes EW. Moonshine and lead. Relationship to the pathogenesis of hyperuricemia and gout. Arthritis Rheum. 1983;26:1057.PubMedCrossRefGoogle Scholar
  796. 796.
    Batuman V, Maesako JK, Haddad B, et al. The role of lead in gout nephropathy. N Engl J Med. 1981; 304:520.PubMedCrossRefGoogle Scholar
  797. 797.
    Poor G, Mituszova M. Saturnine gout. Baillieres Clin Rheumatol. 1989;3:51.PubMedCrossRefGoogle Scholar
  798. 798.
    Cooper WC, Wong O, Kheifets L. Mortality among employees of lead battery plants and lead-producing plants. Scand J Work Environ Health. 1985;11:331.PubMedCrossRefGoogle Scholar
  799. 799.
    Shadick NA, Kim R, Weiss S, et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol. 2000;27:1708.PubMedGoogle Scholar
  800. 800.
    Richet G, Albahary C, Ardaillou R, et al. The kidney in chronic lead poisoning. Rev Fr Etud Clin Biol. 1964;50:188.Google Scholar
  801. 801.
    Richet G, Albahary C, Morel-Maroger L, et al. Renal changes in 23 cases of occupational lead poisoning. Bull Mem Soc Hop Paris. 1966;117:441.Google Scholar
  802. 802.
    Craswell PW, Price J, Boyle PD, et al. Patterns of lead excretion in patients with gout and chronic renal failure: a comparative German and Australian study. Sci Total Environ. 1987;66:17.PubMedCrossRefGoogle Scholar
  803. 803.
    Wright LF, Saylor RP, Cecere FA. Occult lead intoxication in patients with gout and kidney disease. J Rheumatol. 1984;11:517.PubMedGoogle Scholar
  804. 804.
    Craswell PW, Price J, Boyle PD, et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int. 1984;26:319.PubMedCrossRefGoogle Scholar
  805. 805.
    Colleoni N, D’Amico G. Chronic lead accumulation as a possible cause of renal failure in gouty patients. Nephron. 1986;44:32.PubMedCrossRefGoogle Scholar
  806. 806.
    Albahary C, Richet G, Guillaume J, Morel-Maroger L. The kidney in occupational lead poisoning. Arch Mal Prof. 1965;26:5.PubMedGoogle Scholar
  807. 807.
    Sanchez-Fructuoso AI, Torralbo A, Arroyo M, et al. Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transplant. 1996;11:1775.PubMedCrossRefGoogle Scholar
  808. 808.
    Loghman-Adham M. Renal effects of environmental and occupational lead exposure. Environ Health Perspect. 1997;105:928.PubMedCrossRefGoogle Scholar
  809. 809.
    Perazella MA. Lead and the kidney: nephropathy, hypertension, and gout. Conn Med. 1996;60:521.PubMedGoogle Scholar
  810. 810.
    Batuman V. Lead nephropathy, gout, and hypertension. Am J Med Sci. 1993;30:241.CrossRefGoogle Scholar
  811. 811.
    Cledes J, Allain P. Chronic lead nephropathy. Epidemiology and diagnosis. Presse Med. 1992; 21:759.PubMedGoogle Scholar
  812. 812.
    Nolan CV, Shaikh ZA. Lead nephrotoxicity and associated disorders: biochemical mechanisms. Toxicology. 1992;73:127.PubMedCrossRefGoogle Scholar
  813. 813.
    Peitzman SJ, Bodison W, Ellis I. Moonshine drinking among hypertensive veterans in Philadelphia. Arch Intern Med. 1985;145:632.PubMedCrossRefGoogle Scholar
  814. 814.
    Miranda ME, Puig JG, Mateos FA, et al. The role of lead in gout nephropathy reviewed: pathogenic or associated factor? Adv Exp Med Biol. 1991;309A:209.PubMedGoogle Scholar
  815. 815.
    Cullen MR, Robins JM, Eskenazi B. Adult inorganic lead intoxication: presentation of 31 new cases and a review of recent advances in the literature. Medicine. 1983;62:221.PubMedCrossRefGoogle Scholar
  816. 816.
    Batuman V, Landy E, Maesaka JR, Weeden RP. Contribution of lead to hypertension with renal impairment. N Engl J Med. 1983;309:17.PubMedCrossRefGoogle Scholar
  817. 817.
    Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest. 1976;58:260.PubMedCrossRefGoogle Scholar
  818. 818.
    Rempel D. The lead-exposed worker. JAMA. 1989;262:532.PubMedCrossRefGoogle Scholar
  819. 819.
    Occupational exposure to lead. Final standard. 43 Federal Register 220:52952–53014 and 225:54353–54616, 1981, 46 Federal Register 238:60758–60766, 1981.Google Scholar
  820. 820.
    29 CFR 1910.1025 and 1926.62.Google Scholar
  821. 821.
    Chisholm Jr JJ. Mobilization of lead by calcium disodium edetate. Am J Dis Child. 1987;141:1256.Google Scholar
  822. 822.
    Weinberger HL, Post EM, Schneider T, et al. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child. 1987;141:1266.PubMedGoogle Scholar
  823. 823.
    Cory-Slechta DA, Weiss B, Cox C. Mobilization and redistribution of lead over the course of CaEDTA chelation therapy. J Pharmacol Exp Ther. 1987;243:804.PubMedGoogle Scholar
  824. 824.
    Hu H, Aro A, Payton M, et al. The relationship of bone and blood lead to hypertension. The normative aging study. JAMA. 1996;275:1171, 1996;276:1038.PubMedCrossRefGoogle Scholar
  825. 825.
    Hu H, Raabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998;106:1.PubMedCrossRefGoogle Scholar
  826. 826.
    Todd AC. Calculating bone-lead measurement variance. Environ Health Perspect. 2000;108:383, 2000;108:A298.PubMedCrossRefGoogle Scholar
  827. 827.
    Wedeen RP, Ty A, Udasin I, et al. Clinical application of in vivo tibial K-XRF for monitoring lead stores. Arch Environ Health. 1995;50:355.PubMedCrossRefGoogle Scholar
  828. 828.
    Bateman SN, Pejovic-Milic A, Stronach IM, et al. Performance appraisals of digital spectroscopy systems for the measurement of bone lead. Appl Radiat Isot. 2000;53:647.PubMedCrossRefGoogle Scholar
  829. 829.
    Ambrose TM, Al-Lozi M, Scott MG. Bone lead concentrations assessed by in vivo x-ray fluorescence. Clin Chem. 2000;46:1171.PubMedGoogle Scholar
  830. 830.
    Wedeen RD. In vivo tibial XRF measurements of bone lead. Arch Environ Health. 1990;45:69.PubMedCrossRefGoogle Scholar
  831. 831.
    Rosen JF, Markowitz ME, Bijur PE, et al. L-line x-ray fluorescence of cortical bone lead compared with CaNa2EDTA test in lead-toxic children: public health implications. Proc Natl Acad Sci USA. 1989;86:685.PubMedCrossRefGoogle Scholar
  832. 832.
    Friedheim E, Graziano JH, Popovac D, et al. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 1978;2:1234.PubMedCrossRefGoogle Scholar
  833. 833.
    Graziano JH, Siris ES, Lolacono N, et al. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther. 1985;37:431.PubMedCrossRefGoogle Scholar
  834. 834.
    Chisholm Jr JJ, Thomas DJ. Use of 2,3-dimercaptopropane-1-sulfonate in treatment of lead poisoning in children. J Pharmacol Exp Ther. 1985;235:665.Google Scholar
  835. 835.
    Graziano JH, Lolacono NJ, Meyer P. Dose–response of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr. 1988;113:751.PubMedCrossRefGoogle Scholar
  836. 836.
    Chisholm Jr JJ. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Toxicol Clin Toxicol. 1992;30:493.CrossRefGoogle Scholar
  837. 837.
    Tutunji MF, al-Mahasneh QM. Disappearance of heme metabolites following chelation therapy with meso 2,3-dimercaptosuccinic acid (DMSA). J Toxicol Clin Toxicol. 1994;32:267.PubMedCrossRefGoogle Scholar
  838. 838.
    Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97:23.PubMedCrossRefGoogle Scholar
  839. 839.
    Parru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond). 1996;46:41.CrossRefGoogle Scholar
  840. 840.
    Lifshitz M, Hashkanazi R, Phillip M. The effect of 2,3-dimercaptosuccinic acid in the treatment of lead poisoning in adults. Ann Med. 1997;29:83.PubMedCrossRefGoogle Scholar
  841. 841.
    Berlin Jr CM. Lead poisoning in children. Curr Opin Pediatr. 1997;9:173.PubMedCrossRefGoogle Scholar
  842. 842.
    Besunder JB, Super DM, Anderson RL. Comparison of dimercaptosuccinic acid and calcium disodium ethylenediaminetetraacetic acid versus dimercaptopropanol and ethylenediaminetetraacetic acid in children with lead poisoning. J Pediatr. 1997;130:966.PubMedCrossRefGoogle Scholar
  843. 843.
    Miller AL. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev. 1998;3:199.PubMedGoogle Scholar
  844. 844.
    Restek-Samarzija N, Blanusa M, Pizent A, et al. Meso-2,3-dimercaptosuccinic acid in the treatment of occupationally exposed lead workers. Arh Hig Rada Toksikol. 1998;49:137.PubMedGoogle Scholar
  845. 845.
    The Treatment of Lead-Exposed Children (TLC) trial: design and recruitment for a study of the effect of oral chelation on growth and development in toddlers. Paediatr Perinat Epidemiol. 1998;12:313.Google Scholar
  846. 846.
    Lever SZ, Parsons TL. The presence of lead decreases the availability of meso-2,3-dimercaptosuccinic acid for analysis in the monobromobimane assay. Chem Res Toxicol. 1999;12:1057.PubMedCrossRefGoogle Scholar
  847. 847.
    Smith DR, Calacsan C, Woolard D, et al. Succimer and the urinary excretion of essential elements in a primate model of childhood lead exposure. Toxicol Sci. 2000;54:473.PubMedCrossRefGoogle Scholar
  848. 848.
    Chisholm Jr JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol. 2000;38:365.CrossRefGoogle Scholar
  849. 849.
    Ellis MR, Kane KY. Lightening the lead load in children. Am Fam Physician. 2000;62:545, 559.PubMedGoogle Scholar
  850. 850.
    Markowitz M. Lead poisoning. Pediatr Rev. 2000;21:327.PubMedCrossRefGoogle Scholar
  851. 851.
    Eisner ER, Schumacher HR, Sidransky E. Gout and Gaucher disease. Arthritis Rheum. 2000;43:S122.Google Scholar
  852. 852.
    Chang-Lo M, Yam LT, Rubenstone AI, Schwartz SO. Gaucher’s disease associated with chronic lymphocytic leukemia, gout and carcinoma. J Pathol. 1975;116:203–7.PubMedCrossRefGoogle Scholar
  853. 853.
    Liel Y, Hausmann MJ, Moses M. Case report: serendipitous Gaucher’s disease presenting as elevated erythrocyte sedimentation rate due to monoclonal gammopathy. Am J Med Sci. 1991;301:393.PubMedCrossRefGoogle Scholar
  854. 854.
    Shoenfeld Y, Berliner S, Pinkhas J, Beutler E. The association of Gaucher’s disease and dysproteinemias. Acta Haematol (Basel). 1980;64:241.CrossRefGoogle Scholar
  855. 855.
    Turesson T, Rausing A. Gaucher’s disease and benign monoclonal gammopathy. A case report with immunofluorescence study of bone marrow and spleen. Acta Med Scand. 1975;197:507.PubMedCrossRefGoogle Scholar
  856. 856.
    Pratt PW, Estren F, Kochwa S. Immunoglobin abnormalities in Gaucher’s disease. Report of a case. Blood. 1968;31:633.PubMedGoogle Scholar
  857. 857.
    Mark T, Dominguez C, Rywlin AM. Gaucher’s disease associated with chronic lymphocytic leukemia. South Med J. 1982;75:361.PubMedCrossRefGoogle Scholar
  858. 858.
    Kaufman S, Rozenfeld V, Yona R, Varon M. Gaucher’s disease associated with chronic lymphocytic leukaemia. Clin Lab Haematol. 1986;8:321.PubMedCrossRefGoogle Scholar
  859. 859.
    Bruckstein AH, Karanas A, Dire JJ. Gaucher’s disease associated with Hodgkin’s disease. Am J Med. 1980;68:610.PubMedCrossRefGoogle Scholar
  860. 860.
    Cho SY, Sastre M. Coexistence of Hodgkin’s disease and Gaucher’s disease. Am J Clin Pathol. 1976;65:103.PubMedGoogle Scholar
  861. 861.
    Paulson JA, Marti GI, Fink JK, et al. Richter’s transformation of lymphoma complicating Gaucher’s disease. Hematol Pathol. 1989;3:91.PubMedGoogle Scholar
  862. 862.
    Gal R, Gukovsky-Oren S, Floru S, et al. Sequential appearance of breast carcinoma, multiple myeloma and Gaucher’s disease. Haematologica. 1979;73:63.Google Scholar
  863. 863.
    Garfinkel D, Sidi Y, Ben-Bassat M, et al. Coexistence of Gaucher’s disease and multiple myeloma. Arch Intern Med. 1982;142:2229.PubMedCrossRefGoogle Scholar
  864. 864.
    Benjamin D, Joshua H, Djaldetti M, et al. Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher’s disease. Scand J Haematol. 1979;22:179.PubMedCrossRefGoogle Scholar
  865. 865.
    Lamon J, Miller W, Tavassoli M, et al. Specialty conference: multiple myeloma complicating Gaucher’s disease. West J Med. 1982;136:122.Google Scholar
  866. 866.
    Ruestow PC, Levinson DJ, Catchatourian R, et al. Coexistence of IgA myeloma and Gaucher’s disease. Arch Intern Med. 1980;140:1115.PubMedCrossRefGoogle Scholar
  867. 867.
    Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc; 1995. p. 2643.Google Scholar
  868. 868.
    Beutler E, Gelbart T, Kuhl W, et al. Mutations in Jewish patients with Gaucher disease. Blood. 1992;79:1662.PubMedGoogle Scholar
  869. 869.
    Beutler E, Gelbart T, Kuhl W, et al. Identification of the second common Jewish Gaucher disease mutation makes population based screening for the heterozygote state. Proc Natl Acad Sci USA. 1991;88:10544.PubMedCrossRefGoogle Scholar
  870. 870.
    Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science. 1992;256:794.PubMedCrossRefGoogle Scholar
  871. 871.
    Hadler NM, Franck WA, Bress NM, et al. Acute polyarticular gout. Am J Med. 1974;56:715.PubMedCrossRefGoogle Scholar
  872. 872.
    Hench PS. Gout and gouty arthritis. In: Cecil RL, Loeb RF, editors. Textbook of medicine. 9th ed. Philadelphia: Saunders; 1955. p. 643.Google Scholar
  873. 873.
    Scudmore C. A treatise of the nature and course of gout and gravel. 4th ed. London: Mallett; 1823. p. 64.Google Scholar
  874. 874.
    Williamson CS. Gout: a clinical study of one hundred and sixteen cases. JAMA. 1920;74:1625.CrossRefGoogle Scholar
  875. 875.
    Brochner-Mortensen K. One hundred gouty patients. Acta Med Scand. 1941;106:81.CrossRefGoogle Scholar
  876. 876.
    Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970;29:461.PubMedCrossRefGoogle Scholar
  877. 877.
    McCracken JP, Owen PS, Pratt JH. Gout: still a forgotten disease. JAMA. 1946;131:367.CrossRefGoogle Scholar
  878. 878.
    Seegmiller JE. Diseases of purine and pyrimidine metabolism. In: Bondy PK, Rosenberg LE, editors. Metabolic control and disease. 8th ed. Philadelphia: Saunders; 1980. p. 777.Google Scholar
  879. 879.
    Emmerson BT, Wyngaarden JB. Purine metabolism in heterozygous carriers of hypoxanthine-guanine phosphoribosyltransferase deficiency. Science. 1969;166:1533.PubMedCrossRefGoogle Scholar
  880. 880.
    Yu TF. Some unusual features of gouty arthritis in females. Arthritis Rheum. 1977;6:247.CrossRefGoogle Scholar
  881. 881.
    Burch TA, O’Brien WM, Reed R, et al. Hyperuricemia and gout in Mariana Islands. Ann Rheum Dis. 1966;25:114.PubMedGoogle Scholar
  882. 882.
    Reed D, Labarthe D, Stallones R. Epidemiologic studies of serum uric acid levels among Micronesians. Arthritis Rheum. 1972;15:381.PubMedCrossRefGoogle Scholar
  883. 883.
    Prior IAM, Rose BS, Harvey HPB, et al. Hyperuricemia, gout, and diabetic abnormality in Polynesian people. Lancet. 1966;1:333.PubMedCrossRefGoogle Scholar
  884. 884.
    Lennane GAQ, Rose BS, Isdale IC. Gout in Maori. Ann Rheum Dis. 1960;19:120.PubMedCrossRefGoogle Scholar
  885. 885.
    Healey LA, Jones KW. Hyperuricemia in American Samoans. Arthritis Rheum. 1971;14:283.PubMedCrossRefGoogle Scholar
  886. 886.
    Chang SJ, Ko YC, Wang TN, et al. High prevalence of gout and related risk factors in Taiwan’s Aborigines. J Rheumatol. 1997;24:1364.PubMedGoogle Scholar
  887. 887.
    Talbott JH. Gout. New York: Grune & Stratton; 1964. p. 128.Google Scholar
  888. 888.
    Greenhut IJ, Silver RA, Campbell JA. Occurrence of gout in a female: report of an unusual case. Radiology. 1953;60:257.PubMedGoogle Scholar
  889. 889.
    Hill IC. Gout. Lancet. 1938;1:826.CrossRefGoogle Scholar
  890. 890.
    Weingold AB. Gout and pregnancy. Obstet Gynecol. 1960;16:309.PubMedGoogle Scholar
  891. 891.
    Lee FI, Loeffler FE. Gout and pregnancy. J Obstet Gynaecol Br Comm. 1962;69:299.CrossRefGoogle Scholar
  892. 892.
    Friedman EA, Little WA. Pregnancy and gout: a case report. Am J Obstet. 1958;76:913.Google Scholar
  893. 893.
    Batt RE, Cirksena WJ, Lebherz TB. Gout and salt wasting renal disease during pregnancy; Diagnosis, management, and follow-up. JAMA. 1963;186:835.PubMedCrossRefGoogle Scholar
  894. 894.
    Mertz DP, Henninges D, Schwoerer P. Gout and pregnancy. An unusual case with severe hyperlipoproteinaemia. Munch Med Wochenschr. 1972;114:658.PubMedGoogle Scholar
  895. 895.
    Kelsall JT, O’Hanlon DP. Gout during pregnancy. J Rheumatol. 1994;21:1365.PubMedGoogle Scholar
  896. 896.
    Lee IS, Hsu CD. Placental pathologies are not associated with hyperuricemia in preeclamptic pregnancies. Conn Med. 1999;63:459.PubMedGoogle Scholar
  897. 897.
    Fadel HE, Northrop G, Misenhimer HR. Hyperuricemia in pre-eclampsia. A reappraisal. Am J Obstet Gynecol. 1976;125:640.PubMedGoogle Scholar
  898. 898.
    Riedel H, Eisenbach GM, Henkel E, et al. The clinical significance of hyperuricemia for the prognosis of pregnancy toxemia. Fortschr Med. 1978;96:58.PubMedGoogle Scholar
  899. 899.
    Chesley LC. Diagnosis of preeclampsia. Obstet Gynecol. 1985;65:423.PubMedGoogle Scholar
  900. 900.
    Mauy A, Hubel CA, Roberts JA. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174:288.CrossRefGoogle Scholar
  901. 901.
    Mustaphi R, Gopalan S, Dhaliwal L, Surkar AK. Hyperuricemia and pregnancy induced hypertension – reappraisal. Indian J Med Sci. 1996;50:68.PubMedGoogle Scholar
  902. 902.
    Merviel P, Ba R, Beaufils M, et al. Lone hyperuricemia during pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol. 1998;77:145.PubMedCrossRefGoogle Scholar
  903. 903.
    Hsiung R, Hasselmann M, Lutun P, Gordji M. Acute fatty liver of pregnancy. Diagnostic value of hyperuricemia in the pre-jaundice stage. J Gynecol Obstet Biol Reprod (Paris). 1988;17:901.Google Scholar
  904. 904.
    Nishioka N, Mikanagi K. Clinical features of 4,000 gouty subjects in Japan. Adv Exp Med Biol. 1980;122A:47.PubMedCrossRefGoogle Scholar
  905. 905.
    Cornelius R, Schneider HJ. Gouty arthritis in the adult. Radiol Clin North Am. 1988;26:1267.PubMedGoogle Scholar
  906. 906.
    Deesomchok U, Tumrasvin T. A clinical comparison of females and males with gouty arthritis. J Med Assoc Thai. 1989;72:510.PubMedGoogle Scholar
  907. 907.
    Hauge M, Harvold B. Heredity in gout and hyperuricemia. Acta Med Scand. 1955;152:247.PubMedCrossRefGoogle Scholar
  908. 908.
    O’Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1969;31:166.CrossRefGoogle Scholar
  909. 909.
    Popert AJ, Hewitt JV. Gout and hyperuricemia in rural and urban populations. Ann Rheum Dis. 1962;21:154.PubMedCrossRefGoogle Scholar
  910. 910.
    Smyth CJ, Stecher RM, Wolfson WQ. Genetic and endocrine determinants of the plasma urate level. Science. 1948;108:524.CrossRefGoogle Scholar
  911. 911.
    Delbarre F, Braun S, St. Georges-Chaumet F. La goutte feminine (Analyse de quarante observations). Semin Hop (Paris). 1967;43:623.Google Scholar
  912. 912.
    Cowdry SC. Hyperuricemia in infectious mononucleosis. JAMA. 1966;196:319.CrossRefGoogle Scholar
  913. 913.
    Nessan VJ, Geerken RC, Ulvilla J. Uric acid excretion in infectious mononucleosis: a function of increased purine turnover. J Clin Endocrinol Metab. 1974;38:652.PubMedCrossRefGoogle Scholar
  914. 914.
    Diamond H, Sharon E, Holden D. Renal handling of uric acid in sickle cell anemia. In: Sperling O, DeVries A, Wyngaarden JB, editors. Purine metabolism in man. New York: Plenum; 1973. p. 759.Google Scholar
  915. 915.
    Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels. 1961–1980. Arthritis Rheum. 1983;26:87.PubMedCrossRefGoogle Scholar
  916. 916.
    Myers A, Epstein FH, Dodge HJ, Mikkelsen WM. The relationship of serum uric acid to risk factors in coronary heart disease. Am J Med. 1968;45:520.PubMedCrossRefGoogle Scholar
  917. 917.
    Krizek V. Serum uric acid in relation to body weight. Ann Rheum Dis. 1966;25:456.PubMedGoogle Scholar
  918. 918.
    Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary artery disease. Ann Intern Med. 1951;34:1421.PubMedGoogle Scholar
  919. 919.
    Fessel JW, Siegelaub AB, Johnson ES. Correlates and consequences of asymptomatic hyperuricemia. Arch Intern Med. 1973;132:44.PubMedCrossRefGoogle Scholar
  920. 920.
    Loenen HM, Eshuis H, Lowik MR, et al. Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System). J Clin Epidemiol. 1990;43:1297.PubMedCrossRefGoogle Scholar
  921. 921.
    Emmerson BT, Knowles BR. Triglyceride concentrations in primary gout and gout of chronic lead nephropathy. Metabolism. 1971;20:721.PubMedCrossRefGoogle Scholar
  922. 922.
    Heydon S. The workingman’s diet. II. Effect of weight reduction in obese patients with hypertension, diabetes, hyperuricemia and hyperlipidemia. Nutr Metab. 1978;22:141.CrossRef